Viral Infections: Causes, Symptoms, and Treatment

Viral infections are common in human populations and occur when viruses invade the body and replicate within host cells, causing a range of symptoms.^{1 2} These symptoms can vary from mild, such as a runny nose or sore throat, to severe outcomes including respiratory distress or death.^{3 4 5}

A variety of viruses can cause these infections, including influenza viruses, rhinoviruses (responsible for the common cold), and coronaviruses such as SARS-CoV-2, the virus that causes COVID-19.⁶ These viruses are highly contagious and are transmitted through respiratory droplets produced by coughing or sneezing, as well as through contact with contaminated surfaces.⁷ Preventive practices like regular handwashing and minimizing close contact with infected individuals are effective in reducing the risk of transmission.⁸

In addition to affecting individual health, viral infections can have widespread impacts on public health systems, economies, and societies.^{9 10 11 12} The continued emergence of new viral pathogens and mutations in existing ones contribute to increasing challenges in disease prevention and control.^{13 14}

Vaccination remains a primary strategy for reducing the burden of viral infections by lowering transmission rates and mitigating health risks.^{15 16} Effective control of viral diseases depends on a combination of factors, including understanding transmission dynamics, clinical manifestations, treatment options, and public health interventions.¹⁷

Definition and Characteristics

Viruses are unique microscopic entities that challenge traditional definitions of life. Unlike living organisms, viruses cannot reproduce independently; they require a host cell to replicate. This dependency on host cells for their life cycle raises fundamental questions about the nature of life and the mechanisms of infection.^{18 19 20}

Viruses possess a simple structure composed of genetic material surrounded by a protective protein coat known as a capsid.²¹ The genetic material can be either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), which encodes the information necessary for the virus to replicate and produce new viral particles.²²

The capsid serves several functions, including protecting the viral genome from degradation and facilitating the attachment and entry of the virus into host cells.^{23 24} Some viruses also possess a lipid envelope, which is derived from the host cell membrane. This envelope contains viral proteins that assist in the virus’s ability to infect new cells. The presence of the envelope can influence the virus’s stability in the environment and its susceptibility to antiviral treatments.^{25 26 27 28}

Viral Invasion of Host Cells

The process by which viruses invade host cells involves several key steps. First, the virus attaches to specific receptors on the surface of the host cell, a process that is highly selective and often determines the host range of the virus. Once attached, the virus can enter the cell through various mechanisms, including direct fusion with the cell membrane or endocytosis.²⁶

After entering the host cell, the virus hijacks the cellular machinery to replicate its genetic material and produce viral proteins. This replication process can disrupt normal cellular functions, leading to cell damage or death. The newly formed viral particles are then assembled and released from the host cell, often resulting in the host cell’s lysis (bursting) or budding off to infect additional cells.^{29 30}

The invasion of host cells by viruses can have a wide range of consequences for the host’s health. Symptoms of viral infections can vary significantly, from mild manifestations such as a runny nose or fatigue to severe outcomes like pneumonia or organ failure.^{31 32 33} The severity of symptoms often depends on factors such as the type of virus, the host’s immune response, and any underlying health conditions.³⁴

Viral infections can be categorized into three main types based on their interaction with the host’s immune response:

1. Acute Viral Infections: These infections are characterized by a rapid onset of symptoms and a relatively short duration. The immune system typically mounts a strong response, leading to the clearance of the virus. Examples include influenza and the common cold.^{35 36}

2. Chronic Viral Infections: In these cases, the virus persists in the host for an extended period, often leading to ongoing health issues. The immune response may be less effective in controlling the virus, resulting in chronic symptoms. Hepatitis B and HIV are examples of chronic viral infections.^{37 38}

3. Latent Viral Infections: Some viruses can remain dormant within host cells for long periods, reactivating later to cause disease. This latency can evade the immune system, making it challenging to eliminate the virus completely. Herpes simplex virus and varicella-zoster virus (which causes chickenpox and shingles) are examples of latent infections.³⁹

Classification of Viruses

Viruses are classified based on various criteria, including the type of nucleic acid they contain, their structural characteristics, and their modes of replication. This classification is essential for understanding viral behavior, their interactions with host cells, and the development of effective treatments and vaccines.⁴⁰

Nucleic Acid Type

Viruses can be broadly categorized into two main groups based on their nucleic acid: DNA viruses and RNA viruses.

1. DNA Viruses: These viruses contain deoxyribonucleic acid (DNA) as their genetic material.⁴¹ They can be further divided into:

• Double-Stranded DNA (dsDNA) Viruses: These viruses have two complementary strands of DNA. Examples include: Herpesviruses (e.g., Herpes Simplex Virus, Varicella-Zoster Virus), Adenoviruses.^{42 43 44}
• Single-Stranded DNA (ssDNA) Viruses: These viruses have a single strand of DNA. An example is: Parvoviruses (e.g., Parvovirus B19).^{45 46}

2. RNA Viruses: These viruses contain ribonucleic acid (RNA) as their genetic material.⁴⁷ They can be categorized into:

• Single-Stranded RNA (ssRNA) Viruses: These viruses have a single strand of RNA and can be further divided into:
  • Positive-sense ssRNA: This RNA can directly serve as mRNA for protein synthesis. Examples include: Poliovirus, HIV.^{48 49}
  • Negative-sense ssRNA: This RNA must be converted into a positive-sense strand before translation. Examples include: Influenza Virus, Rabies Virus.⁵⁰
• Double-Stranded RNA (dsRNA) Viruses: These viruses have two strands of RNA. An example is: Rotavirus.^{51 52}

Structural Characteristics

Viruses exhibit various structural characteristics that can be classified into three main shapes:

1. Helical Viruses: These viruses have a cylindrical shape formed by a helical arrangement of protein subunits around the nucleic acid. An example is: Tobacco Mosaic Virus.^{53 54}

2. Icosahedral Viruses: These viruses have a spherical shape characterized by a symmetrical structure composed of equilateral triangles. This shape provides a robust and efficient means of enclosing the viral genome. Examples include: Adenovirus, Poliovirus.^{55 56}

3. Complex Viruses: These viruses do not fit neatly into the helical or icosahedral categories and often have more intricate structures. They may possess additional components, such as protein tails or complex envelopes. An example is: Bacteriophage T4, which infects bacteria and has a complex structure with a head and tail.⁵⁷

Modes of Replication

The classification of viruses also involves understanding their modes of replication, which depend on their type of nucleic acid.

• DNA Viruses typically replicate in the host cell’s nucleus, utilizing the host’s cellular machinery for DNA replication and transcription.^{58 59 60}
• RNA Viruses replicate in the cytoplasm. Positive-sense ssRNA viruses can directly use their RNA as mRNA, while negative-sense ssRNA viruses must first synthesize a complementary positive strand.⁴⁹

The classification of viruses based on nucleic acid type, structure, and replication modes has significant implications for understanding their behavior and developing treatments.

• Targeted Therapies: Knowledge of the viral structure and replication mechanisms allows researchers to develop antiviral drugs that specifically target viral processes. For instance, nucleoside analogs can inhibit viral replication by mimicking the building blocks of nucleic acids.^{61 62 63}
• Vaccine Development: Understanding the structural characteristics of viruses aids in vaccine design. Vaccines often utilize inactivated or attenuated forms of viruses or subunit vaccines that present viral proteins to the immune system, eliciting a protective response.^{64 65 66}
• Epidemiology and Control: Classifying viruses helps in tracking outbreaks and understanding transmission dynamics, which is crucial for public health measures.^{67 68}

Modes of Transmission 

Viral infections can spread through several modes. Key transmission methods include:

• Direct contact: Physical interaction with an infected person, such as touching or kissing, can facilitate the spread of viruses like the common cold. When an infected person touches surfaces or objects (fomites) that contain viral particles, they can leave behind infectious agents. If another person subsequently touches the same surface and then touches their face—particularly the mouth, nose, or eyes—they can introduce the virus into their body.^{69 70} Kissing allows for the transfer of saliva, which can harbor viruses. This close physical contact can lead to the direct exchange of viral particles between individuals, increasing the likelihood of transmission, especially for viruses like rhinoviruses that cause the common cold.⁷¹

• Airborne transmission: Some viruses, like the influenza virus, are spread through respiratory droplets that are inhaled by others. Respiratory droplets are produced when an infected person coughs, sneezes, talks, or breathes. These droplets vary in size, with larger droplets (greater than 5 micrometers) typically falling to the ground within a short distance (about 1-2 meters) due to gravity. Smaller droplets, often referred to as aerosols (less than 5 micrometers), can remain suspended in the air for extended periods and travel longer distances, increasing the potential for airborne transmission. Individuals in close proximity to an infected person can inhale these respiratory droplets, leading to the introduction of the virus into their respiratory tract. This process is particularly likely in crowded or enclosed spaces, where ventilation may be poor. Studies have shown that the risk of transmission increases in environments with high population density, such as public transportation, schools, and healthcare settings.^{72 73}

• Vector-borne transmission: Vectors typically acquire viruses when they feed on the blood of an infected host. For instance, when a female mosquito bites a person or animal infected with the Zika virus, the virus enters the mosquito’s bloodstream.^{74 75} The virus can replicate within the mosquito, often in specific tissues such as the salivary glands, which is crucial for subsequent transmission. Once the virus has replicated, the mosquito can transmit it to a new host during subsequent blood meals.⁷⁶ The virus is present in the saliva of the mosquito, which is injected into the host during feeding. This process is similar for ticks, which can transmit viruses like the West Nile virus after acquiring it from infected birds.⁷⁷ The Zika virus outbreak in 2015-2016 is a significant case study. The virus, primarily transmitted by Aedes mosquitoes, led to widespread transmission across the Americas. The Centers for Disease Control and Prevention (CDC) reported approximately 440,000 to 1,300,000 cases of Zika in the U.S. alone, with thousands more in affected countries.^{78 79}

Types of Viral Infections

Viral infections are caused by different types of viruses that can affect various parts of the body.

Respiratory Viral Infections

Respiratory viral infections affect the respiratory tract, including the nose, throat, and lungs. Some common respiratory viral infections include the common cold, influenza, and respiratory syncytial virus (RSV). These infections are highly contagious and can spread easily through coughing and sneezing. Symptoms include cough, runny nose, sore throat, and fever.⁸⁰

The common cold is extremely prevalent, with adults experiencing an average of 4-6 colds per year, while children may have more. The CDC estimates that adults miss approximately 22 million workdays annually due to colds.⁸¹

The 1918 influenza pandemic, caused by the H1N1 virus, infected about one-third of the world’s population and resulted in an estimated 50 million deaths globally.^{82 83}

According to the CDC, influenza affects millions each year, with estimates of 9-41 million illnesses, 140,000-710,000 hospitalizations, and 12,000-52,000 deaths annually in the U.S. alone. Seasonal influenza vaccinations are crucial in reducing the incidence and severity of the disease.^{84 85}

RSV is a leading cause of hospitalization in infants and young children. The CDC reports that RSV leads to approximately 58,000 hospitalizations and 100-500 deaths in children under five years of age each year in the U.S. Additionally, RSV can significantly impact older adults, contributing to morbidity and mortality.^{86 87 88}

Gastrointestinal Viral Infections

Gastrointestinal viral infections affect the digestive system, including the stomach and intestines. Some common gastrointestinal viral infections include norovirus, rotavirus, and adenovirus.^{89 90} These infections are often spread through contaminated food or water, and symptoms include diarrhea, vomiting, and stomach cramps.⁹¹

The CDC estimates that norovirus causes 19-21 million illnesses, 56,000-71,000 hospitalizations, and 570-800 deaths annually in the U.S. alone. Outbreaks are common in settings such as nursing homes and cruise ships, where close quarters facilitate rapid transmission.^{92 93}

Before the introduction of the rotavirus vaccine, the CDC estimated that rotavirus caused around 55,000-70,000 hospitalizations and 200,000 emergency department visits annually among children under five in the U.S. The introduction of vaccination has led to a significant decline in these numbers.^{94 95}

According to the World Health Organization (WHO), rotavirus is responsible for about 215,000 deaths annually in children under five years old in low-income countries. The burden of gastrointestinal viral infections remains a significant public health challenge, particularly in regions with limited access to healthcare and sanitation.^{96 97}

Exanthematous Viral Infections

Exanthematous viral infections are characterized by a rash that appears on the skin. Some common exanthematous viral infections include measles, rubella, and chickenpox.⁹⁸ These infections are highly contagious and can spread through contact with an infected person or their bodily fluids. Symptoms include fever, rash, and general malaise.⁹⁹

According to the World Health Organization (WHO), measles caused approximately 207,500 deaths globally in 2019, primarily among unvaccinated children. The disease can lead to severe complications, including pneumonia, encephalitis, and death.¹⁰⁰

While rubella is generally mild, its impact on pregnant women can be severe. Congenital rubella syndrome can cause serious birth defects, including heart problems, deafness, and intellectual disabilities. The WHO estimates that there are about 100,000 cases of congenital rubella syndrome each year.^{101 102}

Chickenpox is generally mild in children but can lead to serious complications such as bacterial infections, pneumonia, and encephalitis, particularly in adults.¹⁰³ The CDC estimates that before the introduction of the varicella vaccine, chickenpox caused approximately 4 million cases annually in the U.S., leading to about 10,500 hospitalizations and 100-150 deaths each year.¹⁰⁴

Hepatotropic Viral Infections

Hepatotropic viral infections affect the liver and can cause liver inflammation and damage. Some common hepatotropic viral infections include hepatitis A, B, and C.¹⁰⁵ These infections are often spread through contaminated food or water, or through contact with infected bodily fluids.¹⁰⁶ Symptoms include fatigue, nausea, and jaundice.¹⁰⁷

According to the World Health Organization (WHO), there are approximately 1.4 million new cases of hepatitis A globally each year. Vaccination programs have significantly reduced the incidence in many countries.¹⁰⁸

The WHO estimates that about 254 million people were living with chronic hepatitis B globally in 2022. Hepatitis B vaccination has been effective in reducing incidence rates, particularly in endemic regions. For example, in Taiwan, the introduction of the hepatitis B vaccine in 1984 led to a dramatic decrease in the prevalence of the virus among children.¹⁰⁹

The WHO estimates that 56.8 million people were living with chronic hepatitis C globally in 2020. Hepatitis C is a leading cause of liver transplantation and liver cancer. The advent of direct-acting antiviral (DAA) treatments has transformed hepatitis C management. Studies show that these treatments can cure over 95% of cases, significantly reducing the risk of liver disease and cancer.¹¹⁰

Neurotropic Viral Infections

Neurotropic viral infections affect the nervous system, including the brain and spinal cord. Some common neurotropic viral infections include herpes simplex virus, West Nile virus, and Zika virus. These infections are often spread through mosquito bites or contact with infected bodily fluids. Symptoms include headache, fever, and neurological symptoms such as paralysis or seizures.^{111 112 113}

The high prevalence of HSV infections poses significant public health challenges. According to the World Health Organization (WHO), approximately 67% of the global population under 50 is infected with HSV-1.¹¹⁴

A study published in the New England Journal of Medicine reported that HSV-1 is increasingly responsible for genital herpes infections, highlighting a shift in transmission patterns.¹¹⁵

WNV is a leading cause of mosquito-borne disease in the continental United States. The Centers for Disease Control and Prevention (CDC) reports thousands of cases annually, with a significant percentage resulting in severe illness. In 2018, the CDC reported 2,647 cases of WNV in the United States, with 130 fatalities.¹¹⁶

The 2015-2016 Zika outbreak in the Americas raised significant public health concerns due to its association with congenital disabilities. The WHO reported that during the Zika outbreak, Brazil saw a dramatic increase in microcephaly cases in infants born to infected mothers, with over 3,500 reported instances linked to the virus.¹¹⁷

Hemorrhagic Viral Infections

Hemorrhagic viral infections are characterized by bleeding and can be life-threatening. Some common hemorrhagic viral infections include Ebola virus, Marburg virus, and Lassa fever. These infections are often spread through contact with infected bodily fluids, and symptoms include fever, bleeding, and organ failure.¹¹⁸

The case fatality rate for Ebola can vary between outbreaks but is often between 25% and 90%. Survivors may experience long-term health issues, including joint pain, vision problems, and neurological complications. The 2013-2016 West Africa Ebola outbreak resulted in over 28,600 reported cases and more than 11,300 deaths, according to the World Health Organization.¹¹⁹

Similar to Ebola, Marburg virus has a case fatality rate ranging from 24% to 88%, depending on the outbreak and the strain of the virus. Survivors may also experience long-term health complications similar to those seen in Ebola survivors. The 2005 outbreak in Angola resulted in 252 cases and a fatality rate of 83%. This outbreak emphasized the importance of rapid response and containment measures.^{120 121}

The case fatality rate for Lassa fever is approximately 1% to 15%, but it can be higher in certain populations, such as pregnant women. Long-term complications may include hearing loss and other neurological issues. According to the Nigerian Centre for Disease Control, Lassa fever outbreaks have been reported annually, with over 8542 suspected cases reported in 2023 alone.¹²²

Mechanisms of Viral Pathogenesis

Viral Entry and Replication

Viral entry into host cells is the first step in the pathogenesis of viral infections. Different viruses use different mechanisms to enter host cells, but all viruses must ultimately replicate within the host cell to cause disease.¹²³

Some viruses, such as HIV, use receptor-mediated endocytosis to enter host cells, specifically targeting CD4+ T cells. The virus’s envelope glycoprotein (gp120) binds to the CD4 receptor and a co-receptor (CCR5 or CXCR4) on the host cell surface. This interaction triggers the internalization of the virus through endocytosis, allowing it to enter the cytoplasm within an endosomal vesicle.^{124 125}

Once inside, HIV exploits the endosomal environment to facilitate fusion with the endosomal membrane, releasing its RNA genome into the cytoplasm. The virus then utilizes the host’s ribosomes and cellular machinery to replicate its genetic material and produce viral proteins.²⁶

While others, such as influenza virus, use receptor-mediated fusion. It binds to sialic acid-containing receptors on the surface of respiratory epithelial cells. Upon binding, the virus is taken up into the cell through endocytosis, similar to HIV.^{126 127}

However, the critical difference lies in the fusion process. The acidic environment within the endosome triggers a conformational change in the viral hemagglutinin (HA) protein, leading to the fusion of the viral envelope with the endosomal membrane. This fusion releases the viral RNA into the cytoplasm, where it can be replicated and translated using the host’s cellular machinery.^{128 129}

Immune Evasion Strategies

As viruses replicate within host cells, they produce viral proteins that can be recognized by the host’s immune system. This recognition typically triggers an immune response, which includes the activation of innate immunity (such as interferon production) and adaptive immunity (such as the activation of T cells and the production of antibodies).^{130 131} However, many viruses have developed mechanisms to counteract these responses.¹³²

For example, some viruses, such as the influenza virus and certain flaviviruses, produce proteins that inhibit the signaling pathways activated by interferons, which are critical for the antiviral immune response.¹³³ For instance, the NS1 protein of the influenza virus prevents the activation of interferon-stimulated genes, thereby dampening the host’s antiviral response.^{134 135}

Viruses like human cytomegalovirus (HCMV) can interfere with the host’s ability to present viral antigens (Modulation of Antigen Presentation) on major histocompatibility complex (MHC) molecules.¹³⁶ By downregulating MHC class I molecules on infected cells, HCMV can evade recognition by cytotoxic T cells, allowing the virus to persist undetected.¹³⁷

While others rapidly mutate their genetic material to evade recognition by the host immune system. Viruses such as the human immunodeficiency virus (HIV) and the influenza virus frequently undergo genetic mutations that alter their surface proteins.¹³⁸ This phenomenon, known as antigenic drift (in the case of influenza) or antigenic shift (in more dramatic cases) allows these viruses to escape recognition by pre-existing antibodies and T cells, leading to reinfection or persistent infection.^{139 140}

Quasispecies Dynamics: RNA viruses, including HIV and hepatitis C virus (HCV), exist as a diverse population of variants known as quasispecies.^{141 142} This genetic diversity enables rapid adaptation to immune pressures, making it difficult for the host immune system to mount an effective response against all variants simultaneously.^{139 143}

Some viruses, such as herpes simplex virus (HSV) and Epstein-Barr virus (EBV), can establish latency within host cells.¹⁴⁴ SissonsDuring this phase, the virus remains dormant, producing minimal or no viral proteins, which helps it evade immune detection.¹⁴⁵ Reactivation can occur under certain conditions, allowing the virus to replicate and potentially cause disease again.¹⁴⁶

These immune evasion strategies allow viruses to continue replicating within host cells and cause persistent infections.

Viral Transmission

Viral transmission is the final step in the pathogenesis of viral infections. Different viruses are transmitted in different ways, but all viruses must ultimately find a new host to continue their life cycle.¹⁴⁷ Some viruses, such as influenza virus, are transmitted through respiratory droplets that are expelled when an infected person coughs, sneezes, or talks.¹⁴⁸ These droplets can be inhaled by individuals nearby, leading to infection. The proximity of individuals and the density of the population are critical factors that influence the spread of influenza,¹⁴⁹ while others, such as HIV, are transmitted through bodily fluids, including blood, semen, vaginal fluids, and breast milk.¹⁵⁰

Diagnosis of Viral Infections

When it comes to diagnosing viral infections, there are various laboratory testing methods available. These methods help us to identify the causative virus and determine the severity of the infection.

Laboratory Testing

Laboratory testing is the most common method used to diagnose viral infections. It involves the collection of blood, urine, or other bodily fluids to detect the presence of the virus.¹⁵¹ Some of the commonly used laboratory tests include:

1. Viral Culture

Viral culture involves growing the virus in a controlled laboratory environment using host cells. A sample, usually collected from a patient (e.g., throat swab, nasal swab, or tissue biopsy), is inoculated onto cell cultures that support viral growth.²⁰

Significance and Applications:

• Identification: Viral culture is often used to identify the specific type of virus causing the infection, which is essential for determining the appropriate treatment and managing outbreaks.¹⁵²
• Characterization: It allows for the characterization of the virus, including its strain and resistance patterns, which can inform public health responses.¹⁵³

Limitations:

• Time-Consuming: This method can take several days to weeks, as it relies on the virus’s ability to replicate in the culture.¹⁵⁴
• Sensitivity: Some viruses are difficult to culture, and the method may not detect all viral infections, particularly if the patient has already started antiviral treatment.¹⁵⁵

2. Antigen Detection

Antigen detection tests identify specific viral proteins (antigens) present in a patient’s sample, such as blood, urine, or respiratory secretions. These tests typically use techniques like enzyme-linked immunosorbent assay (ELISA) or lateral flow assays.^{156 157}

Significance and Applications:

• Rapid Results: Antigen detection tests provide quicker results compared to viral culture, often within hours, making them useful for immediate clinical decision-making.¹⁵⁸
• Screening: They are particularly valuable for screening purposes, such as in the case of influenza or rapid COVID-19 tests.^{159 160}

Limitations:

• Sensitivity and Specificity: Antigen tests can have lower sensitivity compared to PCR, leading to false negatives, especially in cases of low viral load. They may also vary in specificity, which can result in false positives.¹⁶¹
• Limited Scope: These tests are generally best suited for specific viruses and may not be as effective for detecting a wide range of viral infections.¹⁶²

3. Polymerase Chain Reaction (PCR)

PCR is a molecular diagnostic technique that amplifies specific segments of viral genetic material (DNA or RNA) from a patient’s sample. This method allows for the detection of even minute quantities of viral nucleic acids.^{163 164}

Significance and Applications:

• High Sensitivity and Specificity: PCR is highly sensitive and specific, making it the gold standard for diagnosing many viral infections, including HIV, hepatitis viruses, and SARS-CoV-2.¹⁶⁵
• Early Detection: It can detect viral infections early in the course of the disease, even before symptoms appear or before antibodies are produced.¹⁶¹

Limitations:

• Technical Expertise Required: PCR requires specialized equipment and trained personnel, which may limit its availability in some settings.¹⁶¹
• Cost: The cost of PCR testing can be higher than other methods, potentially affecting accessibility in resource-limited environments.¹⁶¹

Comparison of Diagnostic Methods

Method	Sensitivity	Specificity	Time to Results	Best Suited For
Viral Culture	Moderate	High	Days to weeks	Identifying and characterizing viruses
Antigen Detection	Variable	Variable	Hours	Rapid screening (e.g., influenza)
Polymerase Chain Reaction (PCR)	High	High	Hours to days	Early and accurate diagnosis of viral infections

Each laboratory testing method for diagnosing viral infections has its own strengths and weaknesses. Ultimately, the integration of these testing strategies enhances patient management and informs public health interventions in response to viral outbreaks.

Molecular Diagnostics

Molecular diagnostics is a relatively new method used to diagnose viral infections. It involves the detection of viral genetic material using techniques such as PCR, nucleic acid sequencing, and microarray analysis. These techniques are highly sensitive and specific, allowing for the detection of even low levels of viral genetic material.¹⁶⁶

• Polymerase Chain Reaction (PCR): PCR is a widely used technique that amplifies specific segments of viral DNA or RNA, allowing for the detection of even minute quantities of viral genetic material in a sample. PCR is known for its high sensitivity, enabling the detection of low viral loads that might be missed by other methods. It also has high specificity, as it can target unique sequences of viral nucleic acids, reducing the likelihood of false positives.¹⁶⁷

• Nucleic Acid Sequencing: This method involves determining the exact sequence of nucleotides in a viral genome. It can identify specific strains and mutations within viruses, which is particularly useful for tracking outbreaks and understanding viral evolution.^{168 169} Nucleic acid sequencing provides comprehensive information about the virus, including genetic variations that may affect pathogenicity or resistance to treatments. This level of detail is invaluable for personalized medicine and epidemiological studies.^{170 171}

Microarray Analysis: Microarray analysis uses a grid of probes to simultaneously detect multiple viral nucleic acids in a single sample.^{172 173} This technique can identify various viruses in a multiplex format, making it efficient for broad screening. Microarray analysis allows for the simultaneous detection of multiple viral pathogens, which is particularly beneficial in cases where co-infections may occur.¹⁷⁴ This method enhances diagnostic efficiency and can provide a broader understanding of viral epidemiology.¹⁷⁵

Molecular diagnostics significantly enhance the ability to detect viral infections, particularly in challenging scenarios:

• Low Viral Loads: In infections like HIV or hepatitis, where the viral load may fluctuate, molecular diagnostics can identify the virus even at low levels, facilitating early intervention and monitoring of treatment efficacy.^{176 177}
• Asymptomatic Infections: Molecular techniques can detect viruses in asymptomatic individuals, which is crucial for controlling the spread of infections such as SARS-CoV-2.^{178 179}
• Outbreak Investigation: The ability to rapidly sequence viral genomes aids in tracking outbreaks, understanding transmission dynamics, and identifying potential sources of infection.¹⁸⁰

Here’s a comparison of the advantages of molecular diagnostics over traditional diagnostic approaches in a tabular format:

Feature	Molecular Diagnostics	Traditional Diagnostic Approaches
Sensitivity	High sensitivity; can detect low viral loads	Moderate sensitivity; may miss low-level infections
Specificity	High specificity; targets unique genetic sequences	Variable specificity; risk of cross-reactivity
Speed of Results	Rapid results (hours to days)	Slower results (days to weeks for cultures)
Detection of Early Infections	Effective in detecting infections before antibodies are present	May miss early infections (antibody production takes time)
Multiplexing Capability	Can detect multiple viruses simultaneously (e.g., microarrays)	Generally tests for one virus at a time
Identification of Strains	Can provide detailed genetic information about viral strains and mutations	Limited strain identification; mainly focuses on presence/absence
Adaptability	Easily adapted to new viruses through updated assays	Less flexible; requires development of new tests for new viruses
Use in Asymptomatic Cases	Effective in identifying infections in asymptomatic individuals	Often relies on symptoms or immune response, which may not be present

Serological Methods

Serological methods involve the detection of antibodies (IgM and IgG) produced by the patient’s immune system in response to the viral infection. These tests are useful in determining if a patient has been previously infected with a particular virus.¹⁸¹ ChenSome of the commonly used serological tests include:

• Enzyme-Linked Immunosorbent Assay (ELISA): ELISA is a widely used serological test that detects the presence of specific antibodies in a patient’s serum or plasma.¹⁸² The test involves coating a microplate with viral antigens, adding the patient’s sample, and then using enzyme-linked secondary antibodies that bind to the target antibodies. A substrate is added that produces a measurable color change, indicating the presence and quantity of antibodies.¹⁸³ ELISA is commonly used for screening various viral infections, including HIV, hepatitis B and C, and dengue virus. It is particularly valuable in epidemiological studies and vaccine efficacy assessments.^{184 185}
• Western Blot: Western Blot is a confirmatory test that detects specific proteins (antibodies) in a patient’s serum.¹⁸⁶ The process involves separating proteins by gel electrophoresis, transferring them to a membrane, and then probing with the patient’s serum to identify specific antibodies against viral proteins.¹⁸⁷ A secondary antibody linked to an enzyme or a fluorescent marker is used to visualize the bound antibodies. Western Blot is often used to confirm positive ELISA results for HIV and to detect multiple antibodies in a single test. It is considered a gold standard for confirming certain viral infections.¹⁸⁸

Treatment and Management

Antiviral Medications

Antiviral medications are drugs that target specific viruses and can help reduce the severity and duration of viral infections. Some common antiviral medications include acyclovir for herpes simplex virus, oseltamivir for influenza, and ribavirin for hepatitis C. These medications work by either preventing the virus from replicating or by blocking the virus from entering healthy cells.^{189 190}

1. Inhibiting Viral Replication: Many antiviral drugs interfere with the viral replication process, which is essential for the virus to proliferate within the host. This can occur through several pathways, including¹⁹¹ :

• Nucleoside Analogues: These drugs mimic the building blocks of viral DNA or RNA, leading to premature termination of viral genome synthesis. For example, acyclovir is a nucleoside analogue that specifically targets the herpes simplex virus (HSV) by inhibiting viral DNA polymerase, preventing the virus from replicating.¹⁹²

• Blocking Viral Entry: Some antiviral medications prevent viruses from entering healthy cells, thereby stopping the infection before it can establish itself.¹⁹³ For example:

• Oseltamivir (commonly known as Tamiflu) is an antiviral medication used to treat influenza. It works by inhibiting the neuraminidase enzyme, which is essential for the release of new viral particles from infected cells. By blocking this enzyme, oseltamivir prevents the spread of the virus within the respiratory tract.^{194 195}

• Targeting Viral Proteins: Other antiviral agents may interfere with specific viral proteins required for replication or assembly.^{196 197} For instance:

• Ribavirin is used primarily for hepatitis C and works as a broad-spectrum antiviral that inhibits viral RNA synthesis and can also affect the metabolism of host cells to enhance the immune response.^{198 199}

While antiviral medications can be effective, they have several limitations:

• Not All Viral Infections Are Treatable: Antiviral medications are not effective against all viruses. For example, many viral infections, such as the common cold caused by rhinoviruses, currently lack specific antiviral treatments.²⁰⁰

• Resistance Development: Viruses can develop resistance to antiviral drugs, making them less effective over time. This is particularly concerning in the treatment of chronic infections like HIV and hepatitis C.^{201 202}

• Side Effects: Antiviral medications can cause side effects, which may include nausea, vomiting, diarrhea, and, in some cases, more severe reactions. For instance, ribavirin can cause hemolytic anemia and has teratogenic effects, necessitating caution in certain populations.^{203 204 205}

• Timing of Administration: The effectiveness of antiviral medications often depends on the timing of administration. For many antiviral drugs, early intervention is critical for optimal outcomes, which can complicate treatment in cases where patients seek care later in the disease course.^{206 207}

Vaccination

Vaccination is a preventive measure that can help protect against viral infections. When a vaccine is administered, it introduces antigens—substances that provoke an immune response—into the body. The immune system recognizes these antigens as foreign and mounts a response, which includes the production of antibodies.²⁰⁸ These antibodies are specific to the virus and remain in the body, providing immunity. If the vaccinated individual later encounters the actual virus, their immune system can rapidly recognize and neutralize the threat, preventing illness or reducing its severity.^{209 210}

Common Vaccines

• Flu Vaccine: The flu vaccine is designed to protect against the influenza virus, which can cause severe respiratory illness. It is typically updated annually to match circulating strains of the virus. The vaccine contains inactivated (killed) virus or live attenuated (weakened) virus, prompting the immune system to produce antibodies specific to the influenza virus. Annual vaccination is crucial, as the influenza virus can mutate frequently, and immunity may wane over time.^{211 212}

• Measles, Mumps, and Rubella (MMR) Vaccine: The MMR vaccine provides protection against three viral diseases: measles, mumps, and rubella. It is typically administered in childhood. The MMR vaccine contains live attenuated viruses for each of the three diseases, stimulating a robust immune response. Vaccination has led to a significant decline in the incidence of these diseases, which can cause serious complications.²¹³

• Human Papillomavirus (HPV) Vaccine: The HPV vaccine protects against certain strains of the human papillomavirus that can lead to cervical cancer and other HPV-related cancers. The vaccine introduces virus-like particles that mimic the structure of the HPV virus, prompting the immune system to produce antibodies without causing disease. Vaccination against HPV is recommended for preteens and young adults, as it can significantly reduce the risk of developing HPV-related cancers later in life.^{214 215}

Supportive Care

In addition to antiviral medications and vaccination, supportive care can also be helpful in managing viral infections. Supportive care may include rest, hydration, and over-the-counter medications to relieve symptoms such as fever and pain.

• Rest: Rest is crucial for recovery from any illness, including viral infections. It allows the body to direct its energy toward fighting the infection and repairing tissues. Adequate sleep and reduced physical activity can help strengthen the immune response and speed up recovery.²¹⁶

• Hydration: Staying well-hydrated is essential, especially when experiencing symptoms like fever, vomiting, or diarrhea, which can lead to fluid loss.²¹⁷ Hydration helps maintain bodily functions, supports immune system activity, and aids in the alleviation of symptoms. Water, clear broths, and electrolyte solutions are beneficial in maintaining hydration levels.^{218 219}

• Over-the-Counter Medications: Over-the-counter medications are commonly used to manage symptoms associated with viral infections. These medications do not cure the infection itself but may help alleviate discomfort during recovery. Antipyretics, such as acetaminophen and ibuprofen, are frequently used to reduce fever and relieve pain.^{220 221 222} Decongestants and antihistamines may ease nasal congestion and other upper respiratory symptoms.²²³ Cough suppressants and expectorants can assist in managing coughs and promoting mucus clearance.¹⁷²

Prevention and Control

Public Health Strategies

Several public health strategies have been implemented to prevent and control viral infections, with vaccination being among the most effective. Vaccines stimulate the immune system to produce antibodies against specific viruses, thereby helping to prevent transmission and protect individuals who cannot be vaccinated, such as those with compromised immune systems.

The introduction of the measles vaccine in the 1960s significantly reduced the incidence of the disease. According to the World Health Organization (WHO), global measles deaths decreased by 80% between 2000 and 2017 due to vaccination efforts.^{224 225}

Disease surveillance is a key component of public health strategies for controlling viral infections. It involves the systematic monitoring of disease spread and the early detection of outbreaks, enabling timely implementation of control measures such as quarantine and isolation.^{226 227}

The COVID-19 pandemic highlighted the role of disease surveillance in managing viral outbreaks.²²⁸ Countries that implemented robust surveillance systems, such as South Korea, were able to identify and isolate cases quickly, which contributed to slowing the spread of the virus. For example, South Korea’s rapid testing and contact tracing efforts enabled the identification of clusters and the implementation of targeted restrictions, which helped control case numbers more effectively compared to other countries with delayed responses.^{229 230}

Personal Hygiene Practices

Personal hygiene practices play a key role in preventing the spread of viral infections. Regular handwashing with soap and water is one of the most effective methods to reduce transmission. The Centers for Disease Control and Prevention (CDC) recommends washing hands for at least 20 seconds, ensuring all parts of the hands, including between the fingers and under the nails, are scrubbed.¹⁰²

Covering the mouth and nose when coughing or sneezing helps prevent the release of respiratory droplets that may carry viruses. It is recommended to use a tissue or the inside of the elbow to cover coughs and sneezes, with proper disposal of tissues and handwashing afterward to minimize contamination.

Avoiding close contact with sick individuals and staying home when symptomatic also helps prevent the spread of viral infections. A study published in Nature found that social distancing measures during the COVID-19 pandemic significantly decreased transmission rates and helped control outbreaks.^{231 232}

Quarantine and Isolation

Quarantine and isolation are critical control measures used to prevent the spread of viral infections. Quarantine separates individuals who have been exposed to a virus but are not yet showing symptoms. It is particularly effective during outbreaks of contagious diseases, as it allows health authorities to monitor exposed individuals for symptoms and prevent further transmission.²³³

Isolation, on the other hand, is used to separate individuals who are infected and symptomatic from those who are healthy. It helps reduce the risk of transmission to others, particularly in healthcare settings and crowded environments.^{234 235}

During both quarantine and isolation, strict infection control measures, such as wearing personal protective equipment and practicing good hand hygiene, are essential to minimize the risk of spreading the virus, especially to healthcare workers and others who may come into contact with infected individuals.^{236 237 238}

Emerging and Re-emerging Viral Infections

Emerging and re-emerging viruses present ongoing challenges in the fight against viral infections. Emerging viruses are newly discovered or have recently caused outbreaks, while re-emerging viruses have resurfaced after a period of dormancy.¹¹

One example of an emerging virus is the Zika virus, first identified in 1947, which caused a major outbreak in Brazil and other countries in South America in 2015. Zika virus is primarily transmitted through mosquitoes and can cause birth defects in babies born to infected mothers.²³⁹

Another example is the Nipah virus, which was first identified in Malaysia in 1999. It is a zoonotic virus, meaning it is transmitted from animals to humans. Fruit bats are the primary hosts of Nipah virus, and it can be transmitted to humans through contact with infected animals or consumption of contaminated food.²⁴⁰

On the other hand, re-emerging viruses are those that have been around for a long time but have resurfaced due to various factors such as changes in the environment, human behavior, or viral mutations. One example is the measles virus, which was considered eliminated in the United States in 2000 but has since made a comeback due to low vaccination rates.¹⁴

Global Impact of Viral Infections

Viral infections have a significant impact on global health and economies. This section addresses the economic burden and public health challenges posed by viral infections.

Economic Burden

Viral infections are a significant economic burden on individuals, families, and healthcare systems. The direct and indirect costs associated with viral infections are substantial, including medical expenses, lost productivity, and decreased quality of life.^{241 242 243}

For example, the annual economic burden of influenza in the United States is estimated to be between $71 and $167 billion. This includes costs associated with hospitalizations, outpatient visits, and lost productivity due to illness and death.²⁴⁴

Additionally, viral infections can have a significant impact on the global economy. The COVID-19 pandemic, for instance, has resulted in widespread job losses, decreased economic activity, and increased government spending on healthcare and economic relief programs.^{245 246}

Public Health Challenges

Viral infections pose significant public health challenges, including the spread of disease, outbreaks, and pandemics. The rapid spread of viruses can overwhelm healthcare systems, leading to shortages of medical supplies and personnel.^{247 248}

Moreover, viral infections can disproportionately affect vulnerable populations, including the elderly, children, and individuals with underlying health conditions.²⁴⁹ The COVID-19 pandemic, for example, has had a disproportionate impact on communities of color and low-income individuals.^{250 251 252}

To address these challenges, public health officials must work to prevent the spread of viral infections through vaccination, infection control measures, and public education campaigns. Additionally, healthcare systems must be prepared to respond to outbreaks and pandemics, including increasing capacity and ensuring adequate supplies of medical equipment and personnel.¹⁹⁴

Future Perspectives in Viral Infection Research

As progress continues in understanding viral infections, several key areas of research are expected to be important in the future.

Developing Effective Vaccines

One of the most important areas of research is the development of effective vaccines. Despite significant progress in this field, many viruses still lack effective vaccines. Additionally, the emergence of new viruses, such as the novel coronavirus, underscores the need for ongoing research in vaccine development.²⁵³

Improving Antiviral Therapies

Another important area of research is the development of more effective antiviral therapies. Although several drugs are effective against certain viruses, many viruses still lack effective treatments. Additionally, many existing treatments have significant side effects, limiting their use.^{254 255}

Understanding the Mechanisms of Viral Infection

A third area of research is gaining a better understanding of the mechanisms of viral infection. This includes understanding how viruses enter cells, replicate, and evade the immune system. By understanding these mechanisms, new treatments can be developed to target specific aspects of the viral life cycle.²⁵⁶

Developing Rapid Diagnostic Tests

Finally, the development of rapid diagnostic tests will be critical in the future. Rapid diagnostic tests can help to identify viral infections quickly, allowing for prompt treatment and containment. In addition, rapid diagnostic tests can help to identify outbreaks early, allowing for rapid public health responses.^{257 258}

References

1. Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017a). Epidemiology of Viral Infections. Fenner and White’s Medical Virology, 185–203. https://doi.org/10.1016/B978-0-12-375156-0.00013-8 ↩︎
2. Barker, J., Stevens, D., & Bloomfield, S. F. (2001). Spread and prevention of some common viral infections in community facilities and domestic homes. Journal of Applied Microbiology, 91(1), 7–21. https://doi.org/10.1046/j.1365-2672.2001.01364.x ↩︎
3. Seemungal, T., Harper-Owen, R., Bhowmik, A., Moric, I., Sanderson, G., Message, S., Maccallum, P., Meade, T. W., Jeffries, D. J., Johnston, S. L., & Wedzicha, J. A. (2001). Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 164(9), 1618–1623. https://doi.org/10.1164/ajrccm.164.9.2105011 ↩︎
4. Miyaji, Y., Kobayashi, M., Sugai, K., Hiroyuki Tsukagoshi, Niwa, S., Asako Fujitsuka‐Nozawa, Noda, M., Kunihisa Kozawa, Yamazaki, F., Mori, M., Yokota, S., & Kimura, H. (2013). Severity of respiratory signs and symptoms and virus profiles in Japanese children with acute respiratory illness. Microbiology and Immunology, 57(12), 811–821. https://doi.org/10.1111/1348-0421.12102 ↩︎
5. Ramadori, G. P. (2022). SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death. Medical Sciences, 10(4), 58. https://doi.org/10.3390/medsci10040058 ↩︎
6. Ilyicheva, T. N., Netesov, S. V., & Gureyev, V. N. (2022). COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part I. COVID-19 and Influenza. Molecular Genetics, Microbiology and Virology, 37(1), 1–9. https://doi.org/10.3103/s0891416822010025 ↩︎
7. Dhand, R., & Li, J. (2020). Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. American Journal of Respiratory and Critical Care Medicine, 202(5), 651–659. https://doi.org/10.1164/rccm.202004-1263pp ↩︎
8. Bloomfield, S. F., Aiello, A. E., Cookson, B., O’Boyle, C., & Larson, E. L. (2017). The Effectiveness of Hand Hygiene Procedures in Reducing the Risks of Infections in Home and Community Settings Including Handwashing and alcohol-based Hand Sanitizers. American Journal of Infection Control, 35(10), S27–S64. https://doi.org/10.1016/j.ajic.2007.07.001 ↩︎
9. Sankaran, N., & Weiss, R. A. (2021). Viruses: Impact on Science and Society. Encyclopedia of Virology, 671–680. https://doi.org/10.1016/B978-0-12-814515-9.00075-8 ↩︎
10. Smith, K. M., Machalaba, C. C., Seifman, R., Feferholtz, Y., & Karesh, W. B. (2019). Infectious disease and economics: The case for considering multi-sectoral impacts. One Health, 7, 100080. NCBI. https://doi.org/10.1016/j.onehlt.2018.100080 ↩︎
11. Han, J. J., Song, H. A., Pierson, S. L., Shen-Gunther, J., & Xia, Q. (2023). Emerging Infectious Diseases Are Virulent Viruses-Are We Prepared? An Overview. Microorganisms, 11(11), 2618. https://doi.org/10.3390/microorganisms11112618 ↩︎
12. Luo, G. (George), & Gao, S. (2020). Global health concerns stirred by emerging viral infections. Journal of Medical Virology, 92(4), 399–400. https://doi.org/10.1002/jmv.25683 ↩︎
13. Oroshay Kaiwan, Sethi, Y., Nimrat Khehra, Padda, I., Chopra, H., Chandran, D., Kuldeep Dhama, Chakraborty, C., Md. Aminul Islam, & Nirja Kaka. (2023). Emerging and re-emerging viral diseases, predisposing risk factors, and implications of international travel: a call for action for increasing vigilance and imposing restrictions under the current threats of recently emerging multiple Omicron subvariants. International Journal of Surgery, 109(3), 589–591. https://doi.org/10.1097/js9.0000000000000176 ↩︎
14. Ka-Wai Hui, E. (2006). Reasons for the increase in emerging and re-emerging viral infectious diseases. Microbes and Infection, 8(3), 905–916. https://doi.org/10.1016/j.micinf.2005.06.032 ↩︎
15. Ellwanger, J. H., Veiga, A. B. G. da, Kaminski, V. de L., Valverde-Villegas, J. M., Freitas, A. W. Q. de, & Chies, J. A. B. (2021). Control and prevention of infectious diseases from a One Health perspective. Genetics and Molecular Biology, 44(1 suppl 1). https://doi.org/10.1590/1678-4685-gmb-2020-0256 ↩︎
16. Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M.-G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9(12), 1490. https://doi.org/10.3390/vaccines9121490 ↩︎
17. van Seventer, J. M., & Hochberg, N. S. (2017). Principles of Infectious Diseases: Transmission, Diagnosis, Prevention, and Control. International Encyclopedia of Public Health, 1(PMC7150340), 22–39. ↩︎
18. Taylor, M. W. (2014). What Is a Virus? Viruses and Man: A History of Interactions, 23–40. https://doi.org/10.1007/978-3-319-07758-1_2 ↩︎
19. Nagy, P. D., & Pogany, J. (2011). The dependence of viral RNA replication on co-opted host factors. Nature Reviews Microbiology, 10(2), 137–149. https://doi.org/10.1038/nrmicro2692 ↩︎
20. Louten, J. (2016a). Detection and Diagnosis of Viral Infections. Essential Human Virology, 111–132. https://doi.org/10.1016/B978-0-12-800947-5.00007-7 ↩︎
21. Mateu, M. G. (2013). Assembly, stability and dynamics of virus capsids. Archives of Biochemistry and Biophysics, 531(1-2), 65–79. https://doi.org/10.1016/j.abb.2012.10.015 ↩︎
22. Stone, N. P., Demo, G., Agnello, E., & Kelch, B. A. (2019). Principles for enhancing virus capsid capacity and stability from a thermophilic virus capsid structure. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-12341-z ↩︎
23. Roos, W. H., Ivanovska, I. L., Evilevitch, A., & Wuite, G. J. L. (2007a). Viral capsids: Mechanical characteristics, genome packaging and delivery mechanisms. Cellular and Molecular Life Sciences, 64(12), 1484–1497. https://doi.org/10.1007/s00018-007-6451-1 ↩︎
24. Cliver, D. O. (2009). Capsid and Infectivity in Virus Detection. Food and Environmental Virology, 1(3-4), 123–128. https://doi.org/10.1007/s12560-009-9020-y ↩︎
25. Zeng, L., Li, J., Meilin Lv, Li, Z., Yao, L., Gao, J., Wu, Q., Wang, Z., Yang, X., Tang, G., Qu, G., & Jiang, G. (2023). Environmental Stability and Transmissibility of Enveloped Viruses at Varied Animate and Inanimate Interfaces. PubMed, 1(1), 15–31. https://doi.org/10.1021/envhealth.3c00005 ↩︎
26. Villanueva, R. A., Rouillé, Y., & Dubuisson, J. (2005). Interactions Between Virus Proteins and Host Cell Membranes During the Viral Life Cycle. International Review of Cytology, 171–244. https://doi.org/10.1016/s0074-7696(05)45006-8 ↩︎
27. Rey, F. A., & Lok, S.-M. (2018). Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. Cell, 172(6), 1319–1334. https://doi.org/10.1016/j.cell.2018.02.054 ↩︎
28. Tanjina Tarannum, & Ahmed, S. (2023). Recent development in antiviral surfaces: Impact of topography and environmental conditions. Heliyon, 9(6), e16698–e16698. https://doi.org/10.1016/j.heliyon.2023.e16698 ↩︎
29. Weitzman, M. D., & Fradet-Turcotte, A. (2018). Virus DNA Replication and the Host DNA Damage Response. Annual Review of Virology, 5(1), 141–164. https://doi.org/10.1146/annurev-virology-092917-043534 ↩︎
30. Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017b). Laboratory Diagnosis of Virus Diseases. Fenner and White’s Medical Virology, 135–154. https://doi.org/10.1016/b978-0-12-375156-0.00010-2 ↩︎
31. Kuchar, E., Miśkiewicz, K., Nitsch-Osuch, A., & Szenborn, L. (2015). Pathophysiology of Clinical Symptoms in Acute Viral Respiratory Tract Infections. Advances in Experimental Medicine and Biology, 857, 25–38. https://doi.org/10.1007/5584_2015_110 ↩︎
32. Sumbria, D., Berber, E., Mathayan, M., & Rouse, B. T. (2021). Virus Infections and Host Metabolism—Can We Manage the Interactions? Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.594963 ↩︎
33. Hu, M., Bogoyevitch, M. A., & Jans, D. A. (2020). Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies. Physiological Reviews, 100(4), 1527–1594. https://doi.org/10.1152/physrev.00030.2019 ↩︎
34. Samadizadeh, S., Masoudi, M., Rastegar, M., Salimi, V., Shahbaz, M. B., & Tahamtan, A. (2021). COVID-19: Why does disease severity vary among individuals? Respiratory Medicine, 180, 106356. https://doi.org/10.1016/j.rmed.2021.106356 ↩︎
35. Rai, K. R., Shrestha, P., Yang, B., Chen, Y., Liu, S., Maarouf, M., & Chen, J.-L. (2021). Acute Infection of Viral Pathogens and Their Innate Immune Escape. Frontiers in Microbiology, 12. https://doi.org/10.3389/fmicb.2021.672026 ↩︎
36. Robb, A. (2025). Acute Viral Infections: Symptoms & Treatment – Lesson | Study.com. Study.com. https://study.com/academy/lesson/acute-viral-infections-symptoms-treatment.html ↩︎
37. Deigendesch, N., & Stenzel, W. (2018). Acute and chronic viral infections. Handbook of Clinical Neurology, 227–243. https://doi.org/10.1016/b978-0-12-802395-2.00017-1 ↩︎
38. Mueller, S. N., & Rouse, B. T. (2008). Immune responses to viruses. Clinical Immunology, 421–431. https://doi.org/10.1016/B978-0-323-04404-2.10027-2 ↩︎
39. Traylen, C. M., Patel, H. R., Fondaw, W., Mahatme, S., Williams, J. F., Walker, L. R., Dyson, O. F., Arce, S., & Akula, S. M. (2011a). Virus reactivation: a panoramic view in human infections. Future Virology, 6(4), 451–463. https://doi.org/10.2217/fvl.11.21 ↩︎
40. Louten, J. (2016b). Virus Replication. Essential Human Virology, 1(1), 49–70. https://doi.org/10.1016/B978-0-12-800947-5.00004-1 ↩︎
41. Choi, K. H. (2011). Viral Polymerases. Viral Molecular Machines, 267–304. https://doi.org/10.1007/978-1-4614-0980-9_12  ↩︎
42. Iranzo, J., Krupovic, M., & Koonin, E. V. (2016). The Double-Stranded DNA Virosphere as a Modular Hierarchical Network of Gene Sharing. MBio, 7(4). https://doi.org/10.1128/mbio.00978-16 ↩︎
43. Mody, P. H., Pathak, S., Hanson, L. K., & Spencer, J. V. (2020). Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy. Virology: Research and Treatment, 11, 1178122X2091327. https://doi.org/10.1177/1178122×20913274 ↩︎
44. Szpara, M. L., & Van Doorslaer, K. (2021). Mechanisms of DNA Virus Evolution. Encyclopedia of Virology, 71–78. https://doi.org/10.1016/B978-0-12-809633-8.20993-X ↩︎
45. Berman, J. J. (2012). Group II Viruses. Taxonomic Guide to Infectious Diseases, 231–233. https://doi.org/10.1016/B978-0-12-415895-5.00040-4 ↩︎
46. Malathi, V. G., & Renuka Devi, P. (2019). ssDNA viruses: key players in global virome. VirusDisease, 30(1), 3–12. https://doi.org/10.1007/s13337-019-00519-4 ↩︎
47. Mishra, S. K., & Agrawal, D. (2012). Viruses and Prions. Viruses and Prions , 165–179. https://doi.org/10.1002/9781118301234.ch17 ↩︎
48. Modrow, S., Falke, D., Truyen, U., & Schätzl, H. (2013). Viruses with Single-Stranded, Positive-Sense RNA Genomes. Molecular Virology, 185–349. https://doi.org/10.1007/978-3-642-20718-1_14 ↩︎
49. Payne, S. (2017). Introduction to RNA Viruses. Viruses, 97–105. https://doi.org/10.1016/B978-0-12-803109-4.00010-6 ↩︎
50. Mara, K., Dai, M., Brice, A. M., Alexander, M. R., Tribolet, L., Layton, D. S., & Bean, A. G. D. (2021). Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production. Vaccines, 9(1), 59. https://doi.org/10.3390/vaccines9010059 ↩︎
51. Crawford, S. E., Ramani, S., Tate, J. E., Parashar, U. D., Svensson, L., Hagbom, M., Franco, M. A., Greenberg, H. B., O’Ryan, M., Kang, G., Desselberger, U., & Estes, M. K. (2017). Rotavirus infection. Nature Reviews. Disease Primers, 3(3), 17083. https://doi.org/10.1038/nrdp.2017.83 ↩︎
52. Silvestri, L. S., Taraporewala, Z. F., & Patton, J. T. (2004). Rotavirus Replication: Plus-Sense Templates for Double-Stranded RNA Synthesis Are Made in Viroplasms. Journal of Virology, 78(14), 7763–7774. https://doi.org/10.1128/jvi.78.14.7763-7774.2004 ↩︎
53. STRAUSS, J. H., & STRAUSS, E. G. (2008). The Structure of Viruses. Viruses and Human Disease, 35–62. https://doi.org/10.1016/B978-0-12-373741-0.50005-2 ↩︎
54. Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017c). Virion Structure and Composition. Fenner and White’s Medical Virology, 27–37. https://doi.org/10.1016/B978-0-12-375156-0.00003-5 ↩︎
55. Prasad, B. V. V., & Schmid, M. F. (2011). Principles of Virus Structural Organization. Viral Molecular Machines, 17–47. https://doi.org/10.1007/978-1-4614-0980-9_3 ↩︎
56. Sevvana, M., Klose, T., & Rossmann, M. G. (2021). Principles of Virus Structure. Encyclopedia of Virology, 257–277. https://doi.org/10.1016/B978-0-12-814515-9.00033-3 ↩︎
57. San Martín, C. (2013). Structure and Assembly of Complex Viruses. Subcellular Biochemistry, 329–360. https://doi.org/10.1007/978-94-007-6552-8_11 ↩︎
58. Cann, A. J. (2008). Replication of Viruses. Encyclopedia of Virology, 406–412. https://doi.org/10.1016/B978-012374410-4.00486-6 ↩︎
59. Charman, M., & Weitzman, M. D. (2020). Replication Compartments of DNA Viruses in the Nucleus: Location, Location, Location. Viruses, 12(2), 151. https://doi.org/10.3390/v12020151 ↩︎
60. Rampersad, S., & Tennant, P. (2018). Replication and Expression Strategies of Viruses. Viruses, 55–82. https://doi.org/10.1016/B978-0-12-811257-1.00003-6 ↩︎
61. Zenchenko, A. A., Drenichev, M. S., Il’icheva, I. A., & Mikhailov, S. N. (2021). Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action. Molecular Biology, 55(6), 786–812. https://doi.org/10.1134/S0026893321040105 ↩︎
62. Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., Hamid Khan, A., Saleem, I., Shamim, S., & Malik, A. (2021). A review: Mechanism of action of antiviral drugs. International Journal of Immunopathology and Pharmacology, 35. https://doi.org/10.1177/20587384211002621 ↩︎
63. Kamzeeva, P. N., Aralov, A. V., Alferova, V. A., & Korshun, V. A. (2023). Recent Advances in Molecular Mechanisms of Nucleoside Antivirals. Current Issues in Molecular Biology, 45(8), 6851–6879. https://doi.org/10.3390/cimb45080433 ↩︎
64. Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021). Novel approaches for vaccine development. Cell, 184(6), 1589–1603. https://doi.org/10.1016/j.cell.2021.02.030 ↩︎
65. Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020). Emerging Concepts and Technologies in Vaccine Development. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.583077 ↩︎
66. Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022). The use of viral vectors in vaccine development. Npj Vaccines, 7(1), 1–10. https://doi.org/10.1038/s41541-022-00503-y ↩︎
67. Ryu, S., June Young Chun, Lee, S.-M., Yoo, D., Kim, Y., Sheikh Taslim Ali, & Byung Chul Chun. (2022). Epidemiology and Transmission Dynamics of Infectious Diseases and Control Measures. 14(11), 2510–2510. https://doi.org/10.3390/v14112510 ↩︎
68. Rainwater-Lovett, K., Rodriguez-Barraquer, I., & Moss, W. J. (2016). Viral Epidemiology. Viral Pathogenesis, 241–252. https://doi.org/10.1016/b978-0-12-800964-2.00018-5 ↩︎
69. Castaño, N., Cordts, S. C., Kurosu Jalil, M., Zhang, K. S., Koppaka, S., Bick, A. D., Paul, R., & Tang, S. K. Y. (2021). Fomite Transmission, Physicochemical Origin of Virus–Surface Interactions, and Disinfection Strategies for Enveloped Viruses with Applications to SARS-CoV-2. ACS Omega, 6(10), 6509–6527. https://doi.org/10.1021/acsomega.0c06335 ↩︎
70. Boone, S. A., & Gerba, C. P. (2007). Significance of Fomites in the Spread of Respiratory and Enteric Viral Disease. Applied and Environmental Microbiology, 73(6), 1687–1696. https://doi.org/10.1128/aem.02051-06 ↩︎
71. Limeres Posse, J., Diz Dios, P., & Scully, C. (2017). Viral Diseases Transmissible by Kissing. Saliva Protection and Transmissible Diseases, 53–92. https://doi.org/10.1016/B978-0-12-813681-2.00004-4 ↩︎
72. Richard, M., & Fouchier, R. A. M. (2016). Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential. FEMS Microbiology Reviews, 40(1), 68–85. https://doi.org/10.1093/femsre/fuv039 ↩︎
73. Leung, N. H. L. (2021). Transmissibility and transmission of respiratory viruses. Nature Reviews Microbiology, 19(19), 1–18. https://doi.org/10.1038/s41579-021-00535-6 ↩︎
74. Socha, W., Kwasnik, M., Larska, M., Rola, J., & Rozek, W. (2022). Vector-Borne Viral Diseases as a Current Threat for Human and Animal Health—One Health Perspective. Journal of Clinical Medicine, 11(11), 3026. https://doi.org/10.3390/jcm11113026 ↩︎
75. Rückert, C., & Ebel, G. D. (2018). How do virus-mosquito interactions lead to viral emergence? Trends in Parasitology, 34(4), 310–321. https://doi.org/10.1016/j.pt.2017.12.004 ↩︎
76. Cheng, G., Liu, Y., Wang, P., & Xiao, X. (2016). Mosquito Defense Strategies against Viral Infection. Trends in Parasitology, 32(3), 177–186. https://doi.org/10.1016/j.pt.2015.09.009 ↩︎
77. Schneider, C. A., Calvo, E., & Peterson, K. E. (2021). Arboviruses: How Saliva Impacts the Journey from Vector to Host. International Journal of Molecular Sciences, 22(17), 9173. https://doi.org/10.3390/ijms22179173 ↩︎
78. Plourde, A. R., & Bloch, E. M. (2016). A Literature Review of Zika Virus. Emerging Infectious Diseases, 22(7), 1185–1192. https://doi.org/10.3201/eid2207.151990 ↩︎
79. Chang, C., Ortiz, K., Ansari, A., & Gershwin, M. E. (2016). The Zika outbreak of the 21st century. Journal of Autoimmunity, 68, 1–13. https://doi.org/10.1016/j.jaut.2016.02.006 ↩︎
80. Prasad, S., Lownik, E., & Ricco, J. A. (2016). Viral Infections of the Respiratory Tract. Springer EBooks, 507–517. https://doi.org/10.1007/978-3-319-04414-9_41 ↩︎
81. Heikkinen, T., & Järvinen, A. (2003). The common cold. The Lancet, 361(9351), 51–59. https://doi.org/10.1016/s0140-6736(03)12162-9 ↩︎
82. Taubenberger, J. K., & Morens, D. M. (2019). The 1918 Influenza Pandemic and Its Legacy. Cold Spring Harbor Perspectives in Medicine, 10(10), a038695. https://doi.org/10.1101/cshperspect.a038695 ↩︎
83. Taubenberger, J. K., & Morens, D. M. (2006). 1918 Influenza: the Mother of All Pandemics. Emerging Infectious Diseases, 12(1), 15–22. https://doi.org/10.3201/eid1201.050979 ↩︎
84. Borchering, R. K., Biggerstaff, M., Brammer, L., Budd, A., Garg, S., Fry, A. M., Iuliano, A. D., & Reed, C. (2024). Responding to the Return of Influenza in the United States by Applying Centers for Disease Control and Prevention Surveillance, Analysis, and Modeling to Inform Understanding of Seasonal Influenza. JMIR Public Health and Surveillance, 10, e54340. https://doi.org/10.2196/54340 ↩︎
85. Pelton, S. I., Mould-Quevedo, J. F., & Nguyen, V. H. (2023). The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model. Vaccines, 11(10), 1525. https://doi.org/10.3390/vaccines11101525 ↩︎
86. Suh, M., Movva, N., Jiang, X., Bylsma, L. C., Reichert, H., Fryzek, J. P., & Nelson, C. B. (2022). Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009–2019: A Study of the National (Nationwide) Inpatient Sample. The Journal of Infectious Diseases, 226(Supplement_2), S154–S163. https://doi.org/10.1093/infdis/jiac120 ↩︎
87. Hassan, M. Z., Islam, M. A., Haider, S., Shirin, T., & Chowdhury, F. (2024). Respiratory Syncytial Virus-Associated Deaths among Children under Five before and during the COVID-19 Pandemic in Bangladesh. Viruses, 16(1), 111. https://doi.org/10.3390/v16010111 ↩︎
88. Noble, M., Khan, R. A., Walker, B., Bennett, E., & Gent, N. (2022). Respiratory Syncytial Virus (RSV) associated hospitalisation in children age ≤5 years: A scoping review of literature from 2009-2021. ERJ Open Research, 00593-2021. https://doi.org/10.1183/23120541.00593-2021 ↩︎
89. Sai, G., Yashwitha Sai Pulakurthi, Himaja Dutt Chigurupati, & Surani, S. (2023). Gastrointestinal tract and viral pathogens. Gastrointestinal Tract and Viral Pathogens , 12(3), 136–150. https://doi.org/10.5501/wjv.v12.i3.136 ↩︎
90. Hellysaz, A., Neijd, M., Vesikari, T., Svensson, L., & Hagbom, M. (2023). Viral Gastroenteritis: Sickness Symptoms and Behavioral Responses. MBio, 14(2). https://doi.org/10.1128/mbio.03567-22 ↩︎
91. Orenstein, R. (2020). Gastroenteritis, Viral. Encyclopedia of Gastroenterology, 1(1), 652–657. https://doi.org/10.1016/b978-0-12-801238-3.65973-1 ↩︎
92. Hall, A. J., Lopman, B. A., Payne, D. C., Patel, M. M., Gastañaduy, P. A., Vinjé, J., & Parashar, U. D. (2013). Norovirus Disease in the United States. Emerging Infectious Diseases, 19(8), 1198–1205. https://doi.org/10.3201/eid1908.130465 ↩︎
93. Tsai, H., Yune, P., & Rao, M. (2022). Norovirus disease among older adults. Therapeutic Advances in Infectious Disease, 9, 204993612211367. https://doi.org/10.1177/20499361221136760 ↩︎
94. Dennehy, P. H. (2008). Rotavirus Vaccines: an Overview. Clinical Microbiology Reviews, 21(1), 198–208. https://doi.org/10.1128/cmr.00029-07 ↩︎
95. Ai, C.-E., Steele, M., & Lopman, B. (2020). Disease burden and seasonal impact of improving rotavirus vaccine coverage in the United States: A modeling study. PLOS ONE, 15(2), e0228942. https://doi.org/10.1371/journal.pone.0228942 ↩︎
96. Mado, S., Giwa, F., Abdullahi, S., Alfa, A., Yaqub, Y., Usman, Y., Wammanda, R., Mwenda, J., Isiaka, A., Yusuf, K., & Lawali, N. (2022). Prevalence and characteristics of rotavirus acute gastroenteritis among under-five children in ahmadu bello university teaching hospital, Zaria, Nigeria. Annals of African Medicine, 21(3), 283. https://doi.org/10.4103/aam.aam_31_21 ↩︎
97. Sadiq, A., & Khan, J. (2024). Rotavirus in developing countries: molecular diversity, epidemiological insights, and strategies for effective vaccination. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1297269 ↩︎
98. Scott, L. A., & Stone, M. S. (2003). Viral exanthems. Dermatology Online Journal, 9(3). https://doi.org/10.5070/d33wd095bt ↩︎
99. Kang, J. H. (2015). Febrile Illness with Skin Rashes. Infection & Chemotherapy, 47(3), 155. https://doi.org/10.3947/ic.2015.47.3.155 ↩︎
100. Libbey, J. E., & Fujinami, R. S. (2023). Morbillivirus: A highly adaptable viral genus. Heliyon, 9(7), e18095. https://doi.org/10.1016/j.heliyon.2023.e18095 ↩︎
101. Gong, X., Zheng, C., Fang, Q., Xu, W., & Yin, Z. (2024). A case of congenital rubella syndrome and epidemiology of related cases in China, 2014–2023. Human Vaccines & Immunotherapeutics, 20(1). https://doi.org/10.1080/21645515.2024.2334917 ↩︎
102. Singh, A., Narula, S., Kareem, H., & Devasia, T. (2017). An infant with congenital rubella syndrome in developing India. BMJ Case Reports, 2017. https://doi.org/10.1136/bcr-2017-221665 ↩︎
103. Gershon, A. A., Breuer, J., Cohen, J. I., Cohrs, R. J., Gershon, M. D., Gilden, D., Grose, C., Hambleton, S., Kennedy, P. G. E., Oxman, M. N., Seward, J. F., & Yamanishi, K. (2015). Varicella zoster virus infection. Nature Reviews Disease Primers, 1(1). https://doi.org/10.1038/nrdp.2015.16 ↩︎
104. Impact of U.S. chickenpox vaccination program. (2024, April 22). Chickenpox (Varicella). https://www.cdc.gov/chickenpox/vaccination-impact/index.html ↩︎
105. Adams, D. H., & Hubscher, S. G. (2006). Systemic Viral Infections and Collateral Damage in the Liver. The American Journal of Pathology, 168(4), 1057–1059. https://doi.org/10.2353/ajpath.2006.051296 ↩︎
106. Torre, P., Aglitti, A., Masarone, M., & Persico, M. (2021). Viral hepatitis: Milestones, unresolved issues, and future goals. World Journal of Gastroenterology, 27(28), 4603–4638. https://doi.org/10.3748/wjg.v27.i28.4603 ↩︎
107. None Rosenhelm. (1972). Viral Hepatitis: Introduction. British Medical Bulletin, 28(2), 103–104. https://doi.org/10.1093/oxfordjournals.bmb.a070905 ↩︎
108. Webb, G. W., Kelly, S., & Dalton, H. R. (2020). Hepatitis A and Hepatitis E: Clinical and Epidemiological Features, Diagnosis, Treatment, and Prevention. Clinical Microbiology Newsletter, 42(21), 171–179. https://doi.org/10.1016/j.clinmicnews.2020.10.001 ↩︎
109. World Health Organization: WHO & World Health Organization: WHO. (2024, April 9). Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b ↩︎
110. Tsai, W.-C., Chiang, H.-C., Chiu, Y.-C., Chien, S.-C., Cheng, P.-N., & Chiu, H.-C. (2023). Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment. Life, 13(10), 1964. https://doi.org/10.3390/life13101964 ↩︎
111. Abdullahi, A. M., Sarmast, S. T., & Singh, R. (2020). Molecular Biology and Epidemiology of Neurotropic Viruses. Cureus. https://doi.org/10.7759/cureus.9674 ↩︎
112. Smuts, I., & Lamb, G. V. (2017). Viral Infections of the Central Nervous System. Viral Infections in Children, Volume II, 83–123. https://doi.org/10.1007/978-3-319-54093-1_4 ↩︎
113. Amor, S. (2008). Virus Infections of the Central Nervous System. 853–883. https://doi.org/10.1016/b978-1-4160-4470-3.50052-5 ↩︎
114. Gopinath, D., Koe, K. H., Maharajan, M. K., & Panda, S. (2023). A Comprehensive Overview of Epidemiology, Pathogenesis and the Management of Herpes Labialis. Viruses, 15(1), 225. https://doi.org/10.3390/v15010225 ↩︎
115. Langenberg, A. G. M., Corey, L., Ashley, R. L., Leong, W. P., & Straus, S. E. (1999). A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2. New England Journal of Medicine, 341(19), 1432–1438. https://doi.org/10.1056/nejm199911043411904 ↩︎
116. About West Nile. (2024, May 15). West Nile Virus. https://www.cdc.gov/west-nile-virus/about/index.html ↩︎
117. Adachi, K., & Nielsen-Saines, K. (2018). Zika clinical updates. Current Opinion in Pediatrics, 30(1), 105–116. https://doi.org/10.1097/mop.0000000000000582 ↩︎
118. Pigott, D. C. (2005). Hemorrhagic Fever Viruses. Critical Care Clinics, 21(4), 765–783. https://doi.org/10.1016/j.ccc.2005.06.007 ↩︎
119. Schindell, B. G., Titanji, B. K., Rimoin, A. W., Shaw, S. Y., Kangbai, J. B., & Kindrachuk, J. (2024). Clinical health outcomes of Ebola virus disease survivors eight years post recovery: a cross-sectional study in Sierra Leone. MedRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2024.08.29.24312780 ↩︎
120. Okesanya Olalekan John, Manirambona, E., Olaleke Noah Olabode, Hisham Alhassan Osumanu, Faniyi, A. A., Oumnia Bouaddi, Gbolahan, O. B., Jose Javier Lasala, & Don Eliseo Lucero‐Prisno. (2023). Rise of marburg virus in Africa: a call for global preparedness. Annals of Medicine and Surgery, 85(10), 5285–5290. https://doi.org/10.1097/ms9.0000000000001257 ↩︎
121. Srivastava, S., Sharma, D., Kumar, S., Sharma, A., Rishikesh Rijal, Ankush Asija, Adhikari, S., Sarvesh Rustagi, Sah, S., Zahraa Haleem Al‐qaim, Prashant Bashyal, Mohanty, A., Barboza, J. J., Rodríguez‐Morales, A. J., & Sah, R. (2023). Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1239079 ↩︎
122. Nigeria Centre for Disease Control and Prevention. (n.d.). https://www.ncdc.gov.ng/news/507/lassa-fever-public-health-advisory ↩︎
123. Dimitrov, D. S. (2004). Virus entry: molecular mechanisms and biomedical applications. Nature Reviews Microbiology, 2(2), 109–122. https://doi.org/10.1038/nrmicro817 ↩︎
124. Alkhatib, G. (2009). The biology of CCR5 and CXCR4. Current Opinion in HIV and AIDS, 4(2), 96–103. https://doi.org/10.1097/coh.0b013e328324bbec ↩︎
125. Linos Vandekerckhove, Christ, F., Bénédicte Van Maele, Jan De Rijck, Rik Gijsbers, Van, C., Witvrouw, M., & Zeger Debyser. (2006). Transient and Stable Knockdown of the Integrase Cofactor LEDGF/p75 Reveals Its Role in the Replication Cycle of Human Immunodeficiency Virus. Journal of Virology, 80(4), 1886–1896. https://doi.org/10.1128/jvi.80.4.1886-1896.2006 ↩︎
126. Edinger, T. O., Pohl, M. O., & Stertz, S. (2014). Entry of influenza A virus: host factors and antiviral targets. Journal of General Virology, 95(2), 263–277. https://doi.org/10.1099/vir.0.059477-0 ↩︎
127. Skehel, J. J., & Wiley, D. C. (2000). Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin. Annual Review of Biochemistry, 69(1), 531–569. https://doi.org/10.1146/annurev.biochem.69.1.531 ↩︎
128. White, J. M. (1994). 15 Fusion of Influenza Virus in Endosomes: Role of the Hemagglutinin. Cold Spring Harbor Monograph Archive, 28, 281–301. https://doi.org/10.1101/087969429.28.281 ↩︎
129. Di Lella, S., Herrmann, A., & Mair, Caroline M. (2016). Modulation of the pH Stability of Influenza Virus Hemagglutinin: A Host Cell Adaptation Strategy. Biophysical Journal, 110(11), 2293–2301. https://doi.org/10.1016/j.bpj.2016.04.035 ↩︎
130. Simmons, R. A., Willberg, C. B., & Paul, K. (2013). Immune Evasion by Viruses. ELS. https://doi.org/10.1002/9780470015902.a0024790 ↩︎
131. Vandevenne, P., Sadzot-Delvaux, C., & Piette, J. (2010). Innate immune response and viral interference strategies developed by Human Herpesviruses. Biochemical Pharmacology, 80(12), 1955–1972. https://doi.org/10.1016/j.bcp.2010.07.001 ↩︎
132. Christiaansen, A., Varga, S. M., & Spencer, J. V. (2015). Viral manipulation of the host immune response. Current Opinion in Immunology, 36, 54–60. https://doi.org/10.1016/j.coi.2015.06.012 ↩︎
133. Schulz, K. S., & Mossman, K. L. (2016). Viral Evasion Strategies in Type I IFN Signaling – A Summary of Recent Developments. Frontiers in Immunology, 7. https://doi.org/10.3389/fimmu.2016.00498 ↩︎
134. Talon, J., Horvath, C. M., Polley, R., Basler, C. F., Muster, T., Palese, P., & García-Sastre, A. (2000). Activation of Interferon Regulatory Factor 3 Is Inhibited by the Influenza A Virus NS1 Protein. Activation of Interferon Regulatory Factor 3 Is Inhibited by the Influenza a Virus NS1 Protein, 74(17), 7989–7996. https://doi.org/10.1128/jvi.74.17.7989-7996.2000 ↩︎
135. Marc, D. (2014). Influenza virus non-structural protein NS1: interferon antagonism and beyond. Journal of General Virology, 95(12), 2594–2611. https://doi.org/10.1099/vir.0.069542-0 ↩︎
136. Le-Trilling, V. T. K., & Trilling, M. (2020). Ub to no good: How cytomegaloviruses exploit the ubiquitin proteasome system. Virus Research, 281, 197938. https://doi.org/10.1016/j.virusres.2020.197938 ↩︎
137. Gabor, F., Jahn, G., Sedmak, D. D., & Sinzger, C. (2020). In vivo Downregulation of MHC Class I Molecules by HCMV Occurs During All Phases of Viral Replication but Is Not Always Complete. Frontiers in Cellular and Infection Microbiology, 10. https://doi.org/10.3389/fcimb.2020.00283 ↩︎
138. Burton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012). Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses. Science, 337(6091), 183–186. https://doi.org/10.1126/science.1225416 ↩︎
139. Kim, H., Webster, R. G., & Webby, R. J. (2018). Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunology, 31(2), 174–183. https://doi.org/10.1089/vim.2017.0141 ↩︎
140. Faris Shalayel, M. H. (2020). Molecular basis of Antigenic Reassortment of Influenza Virus. American Journal of Biomedical Science & Research, 8(1), 6–8. https://doi.org/10.34297/ajbsr.2020.08.001223 ↩︎
141. Lauring, A. S., & Andino, R. (2010). Quasispecies Theory and the Behavior of RNA Viruses. PLoS Pathogens, 6(7), e1001005. https://doi.org/10.1371/journal.ppat.1001005 ↩︎
142. Martínez, M. A., Martrus, G., Capel, E., Parera, M., Franco, S., & Nevot, M. (2012). Quasispecies Dynamics of RNA Viruses. Viruses: Essential Agents of Life, 21–42. https://doi.org/10.1007/978-94-007-4899-6_2 ↩︎
143. A. Plauzolles, Lucas, M., & S. Gaudieri. (2013). Hepatitis C Virus Adaptation to T-Cell Immune Pressure. The Scientific World JOURNAL, 2013(1). https://doi.org/10.1155/2013/673240 ↩︎
144. Sissons, J. G. P., Bain, M., & Wills, M. R. (2002). Latency and Reactivation of Human Cytomegalovirus. Journal of Infection, 44(2), 73–77. https://doi.org/10.1053/jinf.2001.0948 ↩︎
145. Murata, T., Sugimoto, A., Inagaki, T., Yanagi, Y., Watanabe, T., Sato, Y., & Kimura, H. (2021). Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation. Viruses, 13(12), 2344. https://doi.org/10.3390/v13122344 ↩︎
146. Traylen, C. M., Patel, H. R., Fondaw, W., Mahatme, S., Williams, J. F., Walker, L. R., Dyson, O. F., Arce, S., & Akula, S. M. (2011b). Virus reactivation: a panoramic view in human infections. Future Virology, 6(4), 451–463. https://doi.org/10.2217/fvl.11.21 ↩︎
147. Garcia-Blanco, M., & Cullen, B. (1991). Molecular basis of latency in pathogenic human viruses. Science, 254(5033), 815–820. https://doi.org/10.1126/science.1658933 ↩︎
148. Valerie Le Sage, Lowen, A. C., & Lakdawala, S. S. (2023). Block the Spread: Barriers to Transmission of Influenza Viruses. Annual Review of Virology, 10(1), 347–370. https://doi.org/10.1146/annurev-virology-111821-115447 ↩︎
149. Spicknall, I. H., Koopman, J. S., Nicas, M., Pujol, J. M., Li, S., & Eisenberg, J. N. S. (2010). Informing Optimal Environmental Influenza Interventions: How the Host, Agent, and Environment Alter Dominant Routes of Transmission. PLoS Computational Biology, 6(10), e1000969. https://doi.org/10.1371/journal.pcbi.1000969 ↩︎
150. Bouabida, K., Chaves, B. G., & Anane, E. (2023). Challenges and barriers to HIV care engagement and care cascade: viewpoint. Frontiers in Reproductive Health, 5(5). https://doi.org/10.3389/frph.2023.1201087 ↩︎
151. Al-Hajjar, S. (2012). Laboratory Diagnosis of Viral Disease. Textbook of Clinical Pediatrics, 923–928. https://doi.org/10.1007/978-3-642-02202-9_75 ↩︎
152. Leland, D. S., & Ginocchio, C. C. (2007). Role of Cell Culture for Virus Detection in the Age of Technology. Clinical Microbiology Reviews, 20(1), 49–78. https://doi.org/10.1128/cmr.00002-06 ↩︎
153. Artika, I. M., Wiyatno, A., & Ma’roef, C. N. (2020). Pathogenic viruses: Molecular detection and characterization. Infection, Genetics and Evolution, 81, 104215. https://doi.org/10.1016/j.meegid.2020.104215 ↩︎
154. Loeffelholz, M. J. (2002). Rapid Diagnosis of Viral Infections. Laboratory Medicine, 33(4), 283–286. https://doi.org/10.1309/e505-ul0y-qx7a-jfmc ↩︎
155. do Nascimento, M. C., Sumita, L. M., de Souza, V. A. U. F., & PannutiC. S. (1998). Detection and Direct Typing of Herpes Simplex Virus in Perianal Ulcers of Patients with AIDS by PCR. Journal of Clinical Microbiology, 36(3), 848–849. https://doi.org/10.1128/jcm.36.3.848-849.1998 ↩︎
156. S. Pavia, C., & M. Plummer, M. (2021). The evolution of rapid antigen detection systems and their application for COVID-19 and other serious respiratory infectious diseases. Journal of Microbiology, Immunology and Infection, 54(5), 776–786. https://doi.org/10.1016/j.jmii.2021.06.003 ↩︎
157. Grandien, M., Pettersson, C. A., Gardner, P. S., Linde, A., & Stanton, A. (1985). Rapid viral diagnosis of acute respiratory infections: comparison of enzyme-linked immunosorbent assay and the immunofluorescence technique for detection of viral antigens in nasopharyngeal secretions. Journal of Clinical Microbiology, 22(5), 757–760. https://doi.org/10.1128/jcm.22.5.757-760.1985 ↩︎
158. Storch, G. A. (2000). Diagnostic Virology. Clinical Infectious Diseases, 31(3), 739–751. https://doi.org/10.1086/314015 ↩︎
159. Anand, A., Bigio, J., MacLean, E., Underwood, T., Pai, N. P., Carmona, S., Schumacher, S. G., & Toporowski, A. (2021). Use cases for COVID-19 screening and surveillance with rapid antigen-detecting tests: a systematic review. Use Cases for COVID-19 Screening and Surveillance with Rapid Antigen-Detecting Tests: A Systematic Review. https://doi.org/10.1101/2021.11.03.21265807 ↩︎
160. Anand, A., Bigio, J., MacLean, E., Underwood, T., Pai, N. P., Carmona, S., Schumacher, S. G., & Toporowski, A. (2022). 317. Use cases for rapid antigen-detecting tests for COVID-19 screening and surveillance: a systematic review. Open Forum Infectious Diseases, 9(Supplement_2). https://doi.org/10.1093/ofid/ofac492.395 ↩︎
161. Pérez-Martínez, Z., Martín, G., Sandoval, M., Rojo-Alba, S., Boga, J. A., Melón, S., & ÁLvarez-Argüelles, M. E. (2021). Comparison of fourteen Rapid Point-of-Care Antigen Tests for SARS-CoV-2: Use & Sensitivity. The Evolution of Rapid Antigen Detection Systems and Their Application for COVID-19 and Other Serious Respiratory Infectious Diseases. https://doi.org/10.21203/rs.3.rs-951263/v1 ↩︎
162. M Korppi, T Heiskanen‐Kosma, Leinonen, M., & Halonen, P. (1993). Antigen and antibody assays in the aetiological diagnosis of respiratory infection in children. Acta Paediatrica, 82(2), 137–141. https://doi.org/10.1111/j.1651-2227.1993.tb12624.x ↩︎
163. Shen, C.-H. (2019). Amplification of Nucleic Acids. Diagnostic Molecular Biology, 215–247. https://doi.org/10.1016/b978-0-12-802823-0.00009-2 ↩︎
164. Seal, S., & Coates, D. (1998). Detection and Quantification of Plant Viruses by PCR. Humana Press EBooks, 469–485. https://doi.org/10.1385/0-89603-385-6:469 ↩︎
165. Yang, S., & Rothman, R. E. (2004). PCR-based Diagnostics for Infectious diseases: uses, limitations, and Future Applications in acute-care Settings. The Lancet Infectious Diseases, 4(6), 337–348. https://doi.org/10.1016/s1473-3099(04)01044-8 ↩︎
166. Cobo, F. (2012). Application of Molecular Diagnostic Techniques for Viral Testing. The Open Virology Journal, 6, 104–114. https://doi.org/10.2174/1874357901206010104 ↩︎
167. Motley, M. P., Bennett-Guerrero, E., Fries, B. C., & Spitzer, E. D. (2020). Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist. Critical Care Explorations, 2(6), e0154. https://doi.org/10.1097/cce.0000000000000154 ↩︎
168. HUNGNES, O., JONASSEN, T. O., JONASSEN, C. M., & GRINDE, B. (2000). Molecular epidemiology of viral infections. How sequence information helps us understand the evolution and dissemination of viruses. Review article. APMIS, 108(2), 81–97. https://doi.org/10.1034/j.1600-0463.2000.d01-31.x ↩︎
169. Jansz, N., & Faulkner, G. J. (2024). Viral genome sequencing methods: benefits and pitfalls of current approaches. Biochemical Society Transactions, 52(3), 1431–1447. https://doi.org/10.1042/BST20231322 ↩︎
170. Colvin, K. (2020). Know Thine Enemy: Viral Genome Sequencing in Outbreaks. EMJ Microbiology & Infectious Diseases, 34–37. https://doi.org/10.33590/emjmicrobiolinfectdis/20f10601 ↩︎
171. Wohl, S., Schaffner, S. F., & Sabeti, P. C. (2016). Genomic Analysis of Viral Outbreaks. Annual Review of Virology, 3(1), 173–195. https://doi.org/10.1146/annurev-virology-110615-035747 ↩︎
172. Wang, D., Coscoy, L., Zylberberg, M., Avila, P. C., Boushey, H. A., Ganem, D., & DeRisi, J. L. (2002). Nonlinear partial differential equations and applications: Microarray-based detection and genotyping of viral pathogens. Proceedings of the National Academy of Sciences, 99(24), 15687–15692. https://doi.org/10.1073/pnas.242579699 ↩︎
173. Lěvěque, N., Renois, F., & Andréoletti, L. (2013). The microarray technology: facts and controversies. Clinical Microbiology and Infection, 19(1), 10–14. https://doi.org/10.1111/1469-0691.12024 ↩︎
174. René Müller, Ditzen, A., Hille, K., Stichling, M., Ralf Ehricht, Illmer, T., Gerhard Ehninger, & Rohayem, J. (2008). Detection of herpesvirus and adenovirus co-infections with diagnostic DNA-microarrays. Journal of Virological Methods, 155(2), 161–166. https://doi.org/10.1016/j.jviromet.2008.10.014 ↩︎
175. Miller, M. B., & Tang, Y.-W. . (2009). Basic Concepts of Microarrays and Potential Applications in Clinical Microbiology. Clinical Microbiology Reviews, 22(4), 611–633. https://doi.org/10.1128/cmr.00019-09 ↩︎
176. Tsang, H.-F., Chan, L. W.-C., Tong, J. C.-H., Wong, H.-T., Lai, C. K.-C., Au, T. C.-C., Chan, A. K.-C., Ng, L. P.-W., Cho, W. C.-S., & Wong, S.-C. C. (2018). Implementation and new insights in molecular diagnostics for HIV infection. Expert Review of Molecular Diagnostics, 18(5), 433–441. https://doi.org/10.1080/14737159.2018.1464393 ↩︎
177. Albertoni, G., Castelo Girão, M. J. B., & Schor, N. (2014). Mini review: Current molecular methods for the detection and quantification of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. International Journal of Infectious Diseases, 25, 145–149. https://doi.org/10.1016/j.ijid.2014.04.007 ↩︎
178. Jiang, C., Li, X., Ge, C., Ding, Y., Zhang, T., Cao, S., Meng, L., & Lu, S. (2021). Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection. Journal of Pharmaceutical Analysis, 11(3), 257–264. https://doi.org/10.1016/j.jpha.2021.03.006 ↩︎
179. Jayakody, H., Kiddle, G., Perera, S., Tisi, L., & Leese, H. S. (2021). Molecular diagnostics in the era of COVID-19. Analytical Methods, 13(34), 3744–3763. https://doi.org/10.1039/d1ay00947h ↩︎
180. Le, V. T. M., & Diep, B. A. (2013). Selected insights from application of whole-genome sequencing for outbreak investigations. Current Opinion in Critical Care, 19(5), 432–439. https://doi.org/10.1097/mcc.0b013e3283636b8c ↩︎
181. Chen, M., Qin, R., Jiang, M., Yang, Z., Wen, W., & Li, J. (2021). Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review. International Journal of Infectious Diseases, 104, 415–422. https://doi.org/10.1016/j.ijid.2021.01.016 ↩︎
182. Hayrapetyan, H., Tran, T., Tellez-Corrales, E., & Madiraju, C. (2023). Enzyme-Linked Immunosorbent Assay: Types and Applications. Methods in Molecular Biology, 2612, 1–17. https://doi.org/10.1007/978-1-0716-2903-1_1 ↩︎
183. Hidayat, R., & Patricia Wulandari. (2021). Enzyme Linked Immunosorbent Assay (ELISA) Technique Guideline. Bioscientia Medicina : Journal of Biomedicine and Translational Research, 5(2), 352–358. https://doi.org/10.32539/bsm.v5i2.228 ↩︎
184. Kim, S.-H. (2017). ELISA for Quantitative Determination of Hepatitis B Virus Surface Antigen. Immune Network, 17(6), 451. https://doi.org/10.4110/in.2017.17.6.451 ↩︎
185. Kabir, M. A., Zilouchian, H., Younas, M. A., & Asghar, W. (2021). Dengue Detection: Advances in Diagnostic Tools from Conventional Technology to Point of Care. Biosensors, 11(7), 206. https://doi.org/10.3390/bios11070206 ↩︎
186. Liu, J., Haorah, J., & Xiong, H. (2013). Western Blotting Technique in Biomedical Research. Current Laboratory Methods in Neuroscience Research, 187–200. https://doi.org/10.1007/978-1-4614-8794-4_14 ↩︎
187. Sigal, L. H. (1996). Molecular Biology and Immunology for Clinicians. JCR Journal of Clinical Rheumatology, 2(3), 141–146. https://doi.org/10.1097/00124743-199606000-00006 ↩︎
188. S. SATHIYAVATHI, V. MATHIVANAN, & SELVI SABHANAYAKAM. (2011). WESTERN BLOT ASSAY OF SELECTED PATIENTS BLOOD INFECED WITH HIV : IN AND AROUND SALEM DISTRICT, TAMILNADU, INDIA. THE SCIENTIFIC TEMPER, 2(1&2), 21–16. https://doi.org/10.58414/scientifictemper.2011.02.1.04 ↩︎
189. Razonable, R. R. (2011). Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. Mayo Clinic Proceedings, 86(10), 1009–1026. https://doi.org/10.4065/mcp.2011.0309 ↩︎
190. Ramírez-Olivencia, G., Estébanez, M., Membrillo, F. J., & Ybarra, M. del C. (2019). Use of ribavirin in viruses other than hepatitis C. A review of the evidence. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.), 37(9), 602–608. https://doi.org/10.1016/j.eimce.2018.05.018 ↩︎
191. Wang, J., Zhu, Q., Xing, X., & Sun, D. (2024). A Mini-Review on the Common Antiviral Drug Targets of Coronavirus. Microorganisms, 12(3), 600–600. https://doi.org/10.3390/microorganisms12030600 ↩︎
192. Seley-Radtke, K. L., & Yates, M. K. (2018). The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Research, 154, 66–86. https://doi.org/10.1016/j.antiviral.2018.04.004 ↩︎
193. Mazzon, M., & Marsh, M. (2019). Targeting viral entry as a strategy for broad-spectrum antivirals. F1000Research, 8, 1628. https://doi.org/10.12688/f1000research.19694.1 ↩︎
194. De Clercq, E. (2006). Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery, 5(12), 1015–1025. https://doi.org/10.1038/nrd2175 ↩︎
195. Davies, B. E. (2010). Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Journal of Antimicrobial Chemotherapy, 65(Supplement 2), ii5–ii10. https://doi.org/10.1093/jac/dkq015 ↩︎
196. Hajjo, R., Sabbah, D. A., Abusara, O. H., Reham Kharmah, & Bardaweel, S. K. (2023). Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. Viruses, 15(2), 568–568. https://doi.org/10.3390/v15020568 ↩︎
197. Idrees, S., Chen, H., Panth, N., Keshav Raj Paudel, & Hansbro, P. M. (2024). Exploring Viral–Host Protein Interactions as Antiviral Therapies: A Computational Perspective. Microorganisms, 12(3), 630–630. https://doi.org/10.3390/microorganisms12030630 ↩︎
198. Te. (2024). Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterology & Hepatology, 3(3). https://pubmed.ncbi.nlm.nih.gov/21960835/ ↩︎
199. Thomas, E., Ghany, M. G., & Liang, T. J. (2012). The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antiviral Chemistry and Chemotherapy, 23(1), 1–12. https://doi.org/10.3851/imp2125 ↩︎
200. Casanova, V., Sousa, F. H., Stevens, C., & Barlow, P. G. (2018). Antiviral therapeutic approaches for human rhinovirus infections. Future Virology, 13(7), 505–518. https://doi.org/10.2217/fvl-2018-0016 ↩︎
201. Pillay, D., & Zambon, M. (1998). Antiviral drug resistance. BMJ, 317(7159), 660–662. https://doi.org/10.1136/bmj.317.7159.660 ↩︎
202. Strasfeld, L., & Chou, S. (2010). Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infectious Disease Clinics of North America, 24(2), 413–437. https://doi.org/10.1016/j.idc.2010.01.001 ↩︎
203. Sung, H., Chang, M., & Saab, S. (2010). Management of Hepatitis C Antiviral Therapy Adverse Effects. Current Hepatitis Reports, 10(1), 33–40. https://doi.org/10.1007/s11901-010-0078-7 ↩︎
204. Knowles, S. R., Phillips, E. J., Dresser, L., & Matukas, L. (2003). Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada. Clinical Infectious Diseases, 37(8), 1139–1142. https://doi.org/10.1086/378304 ↩︎
205. De Franceschi, L., Fattovich, G., Turrini, F., Ayi, K., Brugnara, C., Manzato, F., Noventa, F., Stanzial, A. M., Solero, P., & Corrocher, R. (2000). Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology, 31(4), 997–1004. https://doi.org/10.1053/he.2000.5789 ↩︎
206. Koonin, L. M., & Patel, A. (2018). Timely Antiviral Administration During an Influenza Pandemic: Key Components. American Journal of Public Health, 108(S3), S215–S220. https://doi.org/10.2105/ajph.2018.304609 ↩︎
207. Gonçalves, A., Bertrand, J., Ke, R., Comets, E., Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Rosa Calatrava, M., Mentré, F., Smith, P., Perelson, A. S., & Guedj, J. (2020). Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load. CPT: Pharmacometrics & Systems Pharmacology, 9(9), 509–514. https://doi.org/10.1002/psp4.12543 ↩︎
208. Clem, A. S. (2011). Fundamentals of vaccine immunology. Journal of Global Infectious Diseases, 3(1), 73. https://doi.org/10.4103/0974-777x.77299 ↩︎
209. Neurath, A. R. (2008). Immune Response to Viruses: Antibody-Mediated Immunity. Encyclopedia of Virology, 56–70. https://doi.org/10.1016/B978-012374410-4.00591-4 ↩︎
210. Wiggins, K. B., Smith, M. A., & Schultz-Cherry, S. (2021). The Nature of Immune Responses to Influenza Vaccination in High-Risk Populations. Viruses, 13(6), 1109. https://doi.org/10.3390/v13061109 ↩︎
211. Wong, S.-S. ., & Webby, R. J. (2013). Traditional and New Influenza Vaccines. Clinical Microbiology Reviews, 26(3), 476–492. https://doi.org/10.1128/cmr.00097-12 ↩︎
212. Nuwarda, R. F., Alharbi, A. A., & Kayser, V. (2021). An Overview of Influenza Viruses and Vaccines. Vaccines, 9(9), 1032. https://doi.org/10.3390/vaccines9091032 ↩︎
213. WHITE, S. J., BOLDT, K. L., HOLDITCH, S. J., POLAND, G. A., & JACOBSON, R. M. (2012). Measles, Mumps, and Rubella. Clinical Obstetrics and Gynecology, 55(2), 550–559. https://doi.org/10.1097/grf.0b013e31824df256 ↩︎
214. Kumar, S., Biswas, M., & Jose, T. (2015). HPV vaccine: Current status and future directions. Medical Journal Armed Forces India, 71(2), 171–177. https://doi.org/10.1016/j.mjafi.2015.02.006 ↩︎
215. Williamson, A.-L. (2023). Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses, 15(7), 1440–1440. https://doi.org/10.3390/v15071440 ↩︎
216. Besedovsky, L., Lange, T., & Born, J. (2012). Sleep and immune function. Pflügers Archiv – European Journal of Physiology, 463(1), 121–137. https://doi.org/10.1007/s00424-011-1044-0 ↩︎
217. Horswill, C. A., & Janas, L. M. (2011). Hydration and Health. American Journal of Lifestyle Medicine, 5(4), 304–315. https://doi.org/10.1177/1559827610392707 ↩︎
218. Buyckx, M. E. (2007). Hydration and Health Promotion: A Brief Introduction. Journal of the American College of Nutrition, 26(sup5), 533S534S. https://doi.org/10.1080/07315724.2007.10719654 ↩︎
219. Yash Srivastav, Hameed, A., & Aditya Srivastav. (2024). Rudimentary Overview: Dehydration (Loss of Body Water) Recognition and Management. International Journal of Alternative and Complementary Medicine, 7–11. https://doi.org/10.46797/ijacm.v5i1.585 ↩︎
220. Allen, P. J., & Simenson, S. (2013). Management of Common Cold Symptoms with Over-the-Counter Medications: Clearing the Confusion. Postgraduate Medicine, 125(1), 73–81. https://doi.org/10.3810/pgm.2013.01.2607 ↩︎
221. Eccles, R., Boivin, G., Cowling, B. J., Pavia, A., & Selvarangan, R. (2023). Treatment of COVID-19 symptoms with over the counter (OTC) medicines used for treatment of common cold and flu. Clinical Infection in Practice, 19, 100230. https://doi.org/10.1016/j.clinpr.2023.100230 ↩︎
222. Li, S., Yue, J., Dong, B. R., Yang, M., Lin, X., & Wu, T. (2013). Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008800.pub2 ↩︎
223. De Sutter, A. I., Eriksson, L., & van Driel, M. L. (2022). Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database of Systematic Reviews, 2022(1). https://doi.org/10.1002/14651858.cd004976.pub4 ↩︎
224. World Health Organization: WHO. (2020, July 6). Measles. https://www.who.int/health-topics/measles ↩︎
225. Dabbagh, A., Laws, R. L., Steulet, C., Dumolard, L., Mulders, M. N., Kretsinger, K., Alexander, J. P., Rota, P. A., & Goodson, J. L. (2018). Progress Toward Regional Measles Elimination — Worldwide, 2000–2017. MMWR. Morbidity and Mortality Weekly Report, 67(47), 1323–1329. https://doi.org/10.15585/mmwr.mm6747a6 ↩︎
226. Buckeridge, D., & Cadieux, G. (2006). Surveillance for Newly Emerging Viruses. Perspectives in Medical Virology, 325–343. https://doi.org/10.1016/s0168-7069(06)16013-9 ↩︎
227. Kostkova, P., Saigí-Rubió, F., Eguia, H., Borbolla, D., Verschuuren, M., Hamilton, C., Azzopardi-Muscat, N., & Novillo-Ortiz, D. (2021). Data and Digital Solutions to Support Surveillance Strategies in the Context of the COVID-19 Pandemic. Frontiers in Digital Health, 3. https://doi.org/10.3389/fdgth.2021.707902 ↩︎
228. Jang, Y., Lee, H., & Park, H. (2025). Surveillance System for Infectious Disease Prevention and Management: Direction of Korea’s Infectious Disease Surveillance System. Journal of Korean Medical Science, 40(8). https://doi.org/10.3346/jkms.2025.40.e108 ↩︎
229. Young Joong Kang, Jun-Pyo Myong, Eom, H., Choi, B., Jong Heon Park, & Kim, E.-A. L. (2017). The current condition of the workers’ general health examination in South Korea: a retrospective study. Annals of Occupational and Environmental Medicine, 29(1). https://doi.org/10.1186/s40557-017-0157-0 ↩︎
230. Chang, M. C., Baek, J. H., & Park, D. (2020). Lessons from South Korea Regarding the Early Stage of the COVID-19 Outbreak. Healthcare, 8(3), 229. https://doi.org/10.3390/healthcare8030229 ↩︎
231. Sanchez, J. N., Reyes, G. A., Martínez‐López, B., & Johnson, Christine K. (2022). Impact of social distancing on early SARS‐CoV‐2 transmission in the United States. Zoonoses and Public Health. https://doi.org/10.1111/zph.12909 ↩︎
232. Murphy, C., Wey Wen Lim, Mills, C., Wong, J. Y., Chen, D., Xie, Y., Li, M., Gould, S., Xin, H., Cheung, J., Bhatt, S., Cowling, B. J., & Donnelly, C. A. (2023). Effectiveness of social distancing measures and lockdowns for reducing transmission of COVID-19 in non-healthcare, community-based settings. Philosophical Transactions of the Royal Society A, 381(2257). https://doi.org/10.1098/rsta.2023.0132 ↩︎
233. Nussbaumer-Streit, B., Mayr, V., Dobrescu, A. I., Chapman, A., Persad, E., Klerings, I., Wagner, G., Siebert, U., Christof, C., Zachariah, C., & Gartlehner, G. (2020). Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database of Systematic Reviews, 4(4). https://doi.org/10.1002/14651858.cd013574 ↩︎
234. Landelle, C., Pagani, L., & Harbarth, S. (2013). Is patient isolation the single most important measure to prevent the spread of multidrug-resistant pathogens? Virulence, 4(2), 163–171. https://doi.org/10.4161/viru.22641 ↩︎
235. Andersen, B. M. (2018). Background Information: Isolation Routines. Prevention and Control of Infections in Hospitals, 223–252. https://doi.org/10.1007/978-3-319-99921-0_21 ↩︎
236. Al-Awwal, N., Dweik, F., Mahdi, S., El-Dweik, M., & Anderson, S. H. (2022). A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. Pathogens, 11(3), 368. https://doi.org/10.3390/pathogens11030368 ↩︎
237. Verbeek, J. H., Rajamaki, B., Ijaz, S., Sauni, R., Toomey, E., Blackwood, B., Tikka, C., Ruotsalainen, J. H., & Kilinc Balci, F. S. (2020). Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. Cochrane Database of Systematic Reviews, 5. https://doi.org/10.1002/14651858.cd011621.pub5 ↩︎
238. Aguzie, I. O., Obioha, A. M., Unachukwu, C. E., Okpasuo, O. J., Anunobi, T. J., Ugwu, K. O., Ubachukwu, P. O., & Uju M. E. Dibua. (2024). Hand contamination and hand hygiene knowledge and practices among commercial transport users after the SARS-CoV-2 virus (COVID-19) scare, Enugu State, Nigeria. PLOS Global Public Health, 4(5), e0002627–e0002627. https://doi.org/10.1371/journal.pgph.0002627  ↩︎
239. Gubler, D. J., Vasilakis, N., & Musso, D. (2017). History and Emergence of Zika Virus. The Journal of Infectious Diseases, 216(suppl_10), S860–S867. https://doi.org/10.1093/infdis/jix451 ↩︎
240. Luby, Stephen P., Gurley, Emily S., & Hossain, M.  Jahangir. (2009). Transmission of Human Infection with Nipah Virus. Clinical Infectious Diseases, 49(11), 1743–1748. https://doi.org/10.1086/647951 ↩︎
241. Courville, C., Cadarette, S. M., Wissinger, E., & Alvarez, F. P. (2022). The economic burden of influenza among adults aged 18 to 64: A systematic literature review. Influenza and Other Respiratory Viruses, 16(3), 376–385. https://doi.org/10.1111/irv.12963 ↩︎
242. Rave, N., Mussá, T., Nguyen, A., Pecenka, C., Shaaban, F. L., & Bont, L. J. (2025). Estimating the economic burden of respiratory syncytial virus infection among children <2 years old receiving care in Maputo, Mozambique. Journal of Global Health, 15. https://doi.org/10.7189/jogh.15.04076 ↩︎
243. Faramarzi, A., Soheila Norouzi, Hossein Dehdarirad, Siamak Aghlmand, Hasan Yusefzadeh, & Javad Javan-Noughabi. (2024). The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis. Systematic Reviews, 13(1). https://doi.org/10.1186/s13643-024-02476-6 ↩︎
244. Meltzer, M. I., Cox, N. J., & Fukuda, K. (1999). The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention. Emerging Infectious Diseases, 5(5), 659–671. https://doi.org/10.3201/eid0505.990507 ↩︎
245. Nicola, M., Alsafi, Z., Sohrabi, C., Kerwan, A., Al-Jabir, A., Iosifidis, C., Agha, M., & Agha, R. (2020). The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: a Review. International Journal of Surgery, 78(1), 185–193. NCBI. https://doi.org/10.1016/j.ijsu.2020.04.018 ↩︎
246. Naseer, S., Khalid, S., Parveen, S., Abbass, K., Song, H., & Achim, M. V. (2023). COVID-19 outbreak: Impact on global economy. Frontiers in Public Health, 10(1009393). https://doi.org/10.3389/fpubh.2022.1009393 ↩︎
247. Phadke, I., McKee, A., Conway, J. M., & Shea, K. (2021). Analysing how changes in the health status of healthcare workers affects epidemic outcomes. Epidemiology and Infection, 149. https://doi.org/10.1017/s0950268821000297 ↩︎
248. Filip, R., Puscaselu, R. G., Anchidin-Norocel, L., Dimian, M., & Savage, W. K. (2022). Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: a Review of Pandemic Measures and Problems. Journal of Personalized Medicine, 12(8), 1295. https://doi.org/10.3390/jpm12081295 ↩︎
249. Liu, E., Dean, C., & Elder, K. (2023). Editorial: The impact of COVID-19 on vulnerable populations. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1267723 ↩︎
250. Isasi, F., Naylor, M. D., Skorton, D., Grabowski, D., Hernandez, S., & Montgomery Rice, V. (2021). Patients, Families, and Communities COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. NAM Perspectives, 11. https://doi.org/10.31478/202111c ↩︎
251. Brakefield, W. S., Olusanya, O. A., White, B., & Shaban-Nejad, A. (2022). Social Meltzer, M. I., Cox, N. J., & Fukuda, K. (1999). The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention. Emerging Infectious Diseases, 5(5), 659–671. https://doi.org/10.3201/eid0505.990507 and indicators of COVID-19 among marginalized communities: A scientific review and call to action for pandemic response and recovery. Disaster Medicine and Public Health Preparedness, 17, 1–28. https://doi.org/10.1017/dmp.2022.104 ↩︎
252. Andraska, E. A., Alabi, O., Dorsey, C., Erben, Y., Velazquez, G., Franco-Mesa, C., & Sachdev, U. (2021). Health care disparities during the COVID-19 pandemic. Seminars in Vascular Surgery, 34(3). https://doi.org/10.1053/j.semvascsurg.2021.08.002 ↩︎
253. Fatima Conceição Silva, Mello, P., & da, J. (2023). Vaccine Development against Infectious Diseases: State of the Art, New Insights, and Future Directions. Vaccines, 11(11), 1632–1632. https://doi.org/10.3390/vaccines11111632 ↩︎
254. Gonçalves, B. C., Lopes Barbosa, M. G., Silva Olak, A. P., Belebecha Terezo, N., Nishi, L., Watanabe, M. A., Marinello, P., Zendrini Rechenchoski, D., Dejato Rocha, S. P., & Faccin‐Galhardi, L. C. (2020). Antiviral therapies: advances and perspectives. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12609 ↩︎
255. Richman, D. D., & Nathanson, N. (2016). Antiviral Therapy. Viral Pathogenesis, 271–287. https://doi.org/10.1016/B978-0-12-800964-2.00020-3 ↩︎
256. Green, V. A., Munshi, S. U., Marakalala, M. J., & Mourão, M. M. (2010). Molecular mechanisms of viral infection and propagation: An overview of the second Advanced Summer School in Africa. IUBMB Life, 62(8), 573–583. https://doi.org/10.1002/iub.364 ↩︎
257. Yimer, S. A., Booij, B. B., Tobert, G., Hebbeler, A., Oloo, P., Brangel, P., Jackson, M. L., Jarman, R., Craig, D., Avumegah, M. S., Mandi, H., Endy, T., Wooden, S., Clark, C., Bernasconi, V., Shurtleff, A., & Kristiansen, P. A. (2024). Rapid diagnostic test: a critical need for outbreak preparedness and response for high priority pathogens. BMJ Global Health, 9(4), e014386. https://doi.org/10.1136/bmjgh-2023-014386 ↩︎
258. Bouzid, D., Zanella, M.-C. ., Kerneis, S., Visseaux, B., May, L., Schrenzel, J., & Cattoir, V. (2020). Rapid diagnostic tests for infectious diseases in the emergency department. Clinical Microbiology and Infection, 27(2). https://doi.org/10.1016/j.cmi.2020.02.024 ↩︎